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ABSTRACT: Class B G-protein-coupled receptors (GPCRs) remain an
underexploited target for drug development. The calcitonin receptor (CTR)
family is particularly challenging, as its receptors are heteromers comprising
two distinct components: the calcitonin receptor-like receptor (CLR) or
calcitonin receptor (CTR) together with one of three accessory proteins
known as receptor activity-modifying proteins (RAMPs). CLR/RAMP1
forms a CGRP receptor, CLR/RAMP2 forms an adrenomedullin-1 (AM1)
receptor, and CLR/RAMP3 forms an adrenomedullin-2 (AM2) receptor. The
CTR/RAMP complexes form three distinct amylin receptors. While the
selective blockade of AM2 receptors would be therapeutically valuable, inhibition of AM1 receptors would cause clinically
unacceptable increased blood pressure. We report here a systematic study of structure−activity relationships that has led to the
development of first-in-class AM2 receptor antagonists. These compounds exhibit therapeutically valuable properties with 1000-fold
selectivity over the AM1 receptor. These results highlight the therapeutic potential of AM2 antagonists.
■ INTRODUCTION
G-protein-coupled receptors (GPCRs) are the largest family of
cell surface receptors, with a broad range of physiological and
pathophysiological roles.1 GPCRs have been promising and
successful targets for many therapeutic interventions.2 Func-
tional complexity and pharmacological diversity of GPCRs can
be further influenced by interactions with receptor activity-
modifying proteins (RAMPs). RAMPs are a family of single
transmembrane domain proteins that complex with GPCRs to
facilitate cell surface trafficking, receptor pharmacology as well
as recycling and degradation.3,4 Of the six classes of GPCRs,
members of class B (secretin receptor family) have been most
studied for their interactions with RAMPs and include
calcitonin (CTR) and calcitonin receptor-like (CLR) recep-
tors.4,5 Despite their physiological importance and promising
therapeutic potential, the small number of full-length ligand-
bound structures of class B GPCRs and the limited structural
information on druggable binding sites have made the
development of compounds that target this GPCR family
challenging.6,7 However, a number of structures have been
solved recently8−10 due to advances in cryo-EM technology
and resolution, so that further developments are now more
feasible. Regardless, a number of compounds have been
reported in the past decade, including synthetic modulators of
glucagon, glucagon-like peptide-1, corticotropin-releasing
factor 1, and calcitonin receptor-like receptors.11−13 The
most successful target of class B GPCRs for small molecule
modulators has been the CGRP receptor (comprising CLR
and RAMP1) for which several antagonists and antibodies
have been developed in recent years for the treatment of
migraine.14−18 Some of these have reached the market
including the two oral small molecule antagonists, rimege-
pant19 (Nurtec ODT) and ubrogepant20 (Ubrelvy), as well as
the three injectable signal blocking monoclonal antibodies,
erenumab21 (Aimovig), eptinezumab22 (Vyepti), and galcane-
zumab23 (Emgality). For small molecule antagonists, the
binding site has been shown by X-ray crystallography studies to
be at the interface between RAMP1 and the CLR.24
The selectivity of CGRP receptor antagonists indicates the
potential of exploiting differences between CLR/RAMP
receptor complexes to develop antagonists for other members
of the CLR family, such as receptors of the hormone
adrenomedullin (AM). While the CGRP receptor comprises
CLR and RAMP1, adrenomedullin-1 (AM1) and adrenome-
dullin-2 (AM2) receptors form by the interaction of CLR with
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RAMP2 and RAMP3, respectively.4 AM is a potent vasodilator
that regulates blood pressure.25 While AM signaling through
the AM1 receptor is required for cardiovascular homeostasis,
26
aberrant AM signaling is implicated in cancer development and
progression.27,28 Both AM and the AM2 receptors have been
shown to be upregulated and mediate protumoral processes in
many cancers,29−31 including breast and pancreatic can-
cers.32,33
We have recently reported the discovery of the first-in-class
small molecule antagonists against the AM2 receptor.
34 These
molecules are important new tools that will provide significant
insight into the pharmacology of the CLR/RAMP receptor
family. Additionally, they show promising antitumoral effects
in both in vitro and in vivo models of pancreatic cancer. With a
view to therapeutic potential, the new AM2 receptor
antagonists show 1000-fold selectivity against the AM1
receptor, enabling physiological signaling of AM to continue
through AM1 receptors, lowering the risk of off-target side
effects mediated by the AM1 receptor.
Here, we describe the development and structure−activity
relationships (SARs) of this family of small molecule
antagonists. The chemistry strategy is underpinned by simple
and convergent synthesis routes, and the efficacy of these
compounds was evaluated in in vitro and in vivo models of
breast cancer. The exploration of full drug-like characteristics
(ADME, PK, and in vitro safety markers) of lead compounds is
described by Avgoustou et al.34
■ RESULTS AND DISCUSSION
Design and SAR. There are four significant differences
between RAMP1 and RAMP3 in the vicinity of the small
molecule ligand-binding pocket, namely, R67E, A70T, D71N,
and W74E.34 Of these, we chose W74E as a residue difference
to exploit because of its interaction with ligands that have been
crystallized in the CGRP receptor. The incorporation of a basic
center to interact with the glutamate carboxylate provided a
compelling strategy for designing AM2 receptor-selective
ligands. The W74E change is also seen when comparing
RAMP1 with RAMP2; therefore, the simplest approach to
building a pseudo (hybrid)-model of the AM2 receptor-binding
pocket was to transpose the side-chain conformation of
Glu105 from the RAMP2 crystal structure (PDB code
3AQF35) into the Trp74 position of the CGRP receptor
crystal structure (PDB code 3N7R36). Alternative conforma-
tions of the glutamate side chain were examined but the results
were not significantly affected. As all our compounds were
active, at least to some extent at both CGRP and AM2
receptors, it was decided to use this slightly modified structure
of the CGRP receptor as a basis for docking, making the
assumption that the binding modes in both CGRP and AM2
receptors would be the same.37
The crystal structure of MK-3207 has been solved,38 but the
only information published is a figure that shows a stick
representation of the ligand and a surface representation of the
protein. The ligand was docked such that it replicated as much
of the information presented in this image as possible.
Conformations of ligands were initially built using Open
Babel (version 2.3.1). The starting conformation of the CLR-
binding spiro ring system was fixed to replicate the
configuration observed in the image, and the resultant
conformer was refined by density functional theory (DFT)
minimization in ORCA.39 Docking was carried out using
GOLD,40 tethering the lactam or equivalent portion of the
headgroup onto that observed in the PDB structure of
telcagepant bound to the ectodomain of the CGRP receptor
(PDB code 3N7R36) and generating 30 docks per compound
using default options. Results were processed using an in-house
script to cluster the docks and assess the quality of hydrogen
bonds, identifying docks with high GOLD scores, no
antihydrogen bonds, and, where relevant, a high-quality
Figure 1. Docking of telcagepant (magenta) and compound 1 (purple) in our pseudo (hybrid)-model of the AM2 receptor-binding pocket. The
Glu74 residue from RAMP3 is indicated in green. CLR is shown in yellow and RAMP3 in cyan. Hydrogen bonds are shown as dotted lines.
Compound 1 has similar spatial occupancy and interactions to telcagepant (magenta) as observed in the CGRP receptor crystal structure (PDB
code 3N7R36).
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interaction with the glutamate (distance between heavy atoms
of 2.7−3.5 Å and the angle subtended at donor H of close to
180°).
The dock of the published structure of compound 1, a
CGRP receptor antagonist with an encouraging activity against
the AM2 receptor,
41 overlaid well with telcagepant, preserving
the interactions of the tethered headgroup (Figure 1). In
addition, the carbonyl oxygen atom of the pivalamide
substituent formed a hydrogen bond with the indole NH of
CLR Trp72. The residue implicated in selectivity, W74E,
appeared to be accessible from the ortho position of the phenyl
ring, suggesting a position to introduce basic substituents
(Figure 1).
From starting point compound 1, the aim was to design and
synthesize compounds that would bind strongly to the AM2
receptor. Our strategy assumed that modulating the RAMP
structural binding fragment, while conserving the CLR-binding
fragment, would lead to the successful identification of
RAMP3-binding groups (Figure 2).
We first set out to investigate the antagonist behavior of
several known CLR-binding fragments attached to the RAMP-
binding motif present in 1. As shown in Table 1, combining a
set of known CLR fragments from CGRP inhibitors
(specifically, telcagepant/rimegepant, MK-3207, and olcege-
pant) with the RAMP-binding portion of 1 led to analogues
2−4, of which indene 3 showed moderately improved
inhibition at the AM2 receptor (pIC50 = 6.7) relative to the
initial indene lead 1, with non-indenes losing measurable
activity.
Working on the basis that the CLR fragment in 3 was
optimal for our purposes, we implemented the strategy of
incorporating a basic moiety into the benzyl side chain of the
RAMP fragment. The pIC50 data of our compounds against
AM2, together with data for selected compounds against AM1
and CGRP, are summarized in Table 2. Compounds bearing a
heterocyclic or heteroaromatic ring showed reduced potency
(compounds 5−8), while the activity was broadly maintained
when a pyrrolidine-substituted benzyl group or an indazole was
incorporated (compounds 9, 10). Pleasingly, aniline 11
provided our first significant increase in receptor affinity,
with a pIC50 of 8.2. Activity was maintained when the aniline
was changed to a benzylic amine (compound 12) but changing
to the corresponding benzylic alcohol or moving the
aminomethyl group to the meta-position led to a marked
decrease in activity (compounds 13, 14). Returning to the
positional scanning at the ortho-benzyl position, we were
interested in finding that a primary amide, homologated
primary amine, and tethered secondary amine produced pIC50
values of around 7 (compounds 15−17). In contrast, benzylic
morpholine, imidazole, pyridine, and nitrile groups performed
poorly (compounds 18−21), as did the aminomethyl analogue
attached to a pyridine ring (compound 22). The incorporation
of further basic residues via an imidazole (compound 23) or by
changing to a guanidine moiety (compound 24) failed to
improve potency. However, simply homologating the amino-
methyl group to secondary amine 23 gave a dramatic increase
in affinity, providing our first inhibitor in the subnanomolar
range (compound 25). Further efforts to increase activity by
increasing alkylation at various points around the benzylic
aminomethyl fragment did not result in a significant enhance-
ment of activity (compounds 25−29). Overall, this study
highlighted the importance of the spatial orientation of the
basic group (e.g., compound 12 versus compound 14) and the
sensitivity of the receptor to steric bulk in the RAMP3-binding
region (cf. compounds 25, 27, 18). Finally, in all cases where
compounds were cross-screened against AM1 receptor, very
weak potency was observed. Although RAMP2 contains Asp
and Glu at the equivalent positions, it is believed that other
significant differences in the pocket are responsible for the lack
of activity at the AM1 receptor. For example, (i) residue 70
(Ala in RAMP1 and Thr in RAMP3) is the much larger Arg in
RAMP2, which, in crystal structures (PDB code 4RWF42), sits
in space that would clash with these ligands, and (ii) Trp84 in
RAMP3, which makes significant interactions with the core of
these ligands, is a Trp in RAMP3 but the smaller Phe in
RAMP2, which is unable to contact the ligands and therefore
leaving an energetically unfavorable void.
■ CHEMISTRY
The modular nature of our inhibitors offered simple and
efficient synthetic routes from commercially available and
inexpensive starting materials, allowing us rapidly to identify
analogues with increased potency against the AM2 receptor.
The general synthetic route is shown in Scheme 1. The
reductive amination of the appropriate aldehyde with Ala-OMe
Figure 2. Compound 1 structure analysis for SAR.
Table 1. Investigating the Effect of Different CLR-Binding
Fragments on the Antagonism against the AM2 Receptor
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Table 2. pIC50 Values of RAMP with N-Alkyl-Substituent SAR Library against the AM2 Receptor Compared to Those of AM1
and CGRP Receptorsa
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or simple alkylation of amines with ethyl bromoacetate
provided intermediates that were subjected to acylation with
pivaloyl chloride and saponification to produce the desired
RAMP-binding acids. Amide bond formation promoted by
EDCI or HATU generated the final RAMP−CLR inhibitor
constructs that could be further manipulated using standard
functional group transformations (detailed synthetic proce-
dures are described in the Supporting Information).
With a robust method in hand, we next wanted to assess the
impact of the stereochemistry of the CLR-binding unit on
activity as it is known to have an impact on the CGRP
potency.43,44 For example, in the case of MK-3207, the
analogue with a CLR-binding group in the (S) rather than (R)
configuration reduces potency by 100-fold, from 0.12 to 10
nM. Indeed, as discussed in our preliminary report on this
work,34 the (R)-enantiomer of 25 (isolated by the preparative
chiral high-performance liquid chromatography (HPLC) of the
racemate) was found to have improved potency over the
corresponding (S)-enantiomer (pIC50 = 9.2 versus 7.2), so we
set about devising an efficient synthesis of (R)-25.
The synthesis of the (R)-CLR-binding motif amine 30 was
accomplished by a modification of the method reported by
Bulger and Yasuda.45,46 An enantioselective phase transfer-
catalyzed alkylation of 31 with 32 was found to give a higher
degree of selectivity when excess sodium hydroxide was
employed in toluene/H2O. This method allowed us to
generate intermediate 33 in an ∼90% yield with 83% ee
although this sample could be delivered in >99% ee after a
single recrystallization (Scheme 2). Finally, the removal of the
Bn- and tBu- groups gave the (R)-enantiomer of the desired
amine 30 with >99% ee. Slow crystallization of 30 in methanol
allowed us to confirm the product stereochemistry using
single-crystal X-ray diffraction.
The docked pose of (R)-25 was consistent with that of 1 in
the placement of their common substructures. As predicted,
the protonated amine formed salt bridges with the carboxylate
of Glu74 and the carboxylate of Asp71 (an asparagine
carboxamide in RAMP3), possibly explaining why it is
tolerated in both CGRP and AM2. The apparent preference
for RAMP3 over RAMP1 could be explained by the
interactions with the acid of Glu74 and the carbonyl of
Table 2. continued
and: not determined.
Scheme 1. Reagents and General Conditionsa
a(a) Ethyl bromoacetate, N,N-diisopropylethylamine (DIPEA), dimethylformamide (DMF) or benzylbromoacetate, Et3N, tetrahydrofuran (THF;
when amine was used) and glycine ethyl ester hydrochloride, NaBH3CN, MeOH (when aldehyde or ketone was used); (b) (i) PivCl, DIPEA,
dichloromethane (DCM); (ii) 2.5 N NaOH, MeOH or LiOH·H2O, MeOH/THF/H2O; (c) HATU, NMM, DM or EDCI, HOAt, DIPEA, DMF.
Scheme 2. Reagents and Conditionsa
a(a) (i) NaOH, PTC*, toluene/H2O; (ii) recrystallized from toluene/MeOH; (b) (i) MsOH, toluene, 90 °C; (ii) ∼10% Pd/C, H2, HCl/MeOH,
rt, o/n. PTC*: Chiral phase transfer catalyst. Please see Experimental Section for details.
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Asn71 being more favorable than the indole of Trp74 and the
acid of Asp71, either because of differences in the salt bridge
geometry or because the carboxamide is a preferred partner
when compared with the indole (Figure 3).
Antitumor Effect of (±)-25. In vitro viability and in vivo
subcutaneous xenograft models were used to determine
antitumor effects of the AM2 receptor antagonist (±)-25,
using the highly aggressive triple-negative breast cancer cell
line MDA-MB-231. (±)-25 decreased the MDA-MB-231
viability by 55% after 3 days of daily treatment at 10 μM
concentration (Figure 4a; p < 0.01). For the in vivo xenograft
study, MDA-MB-231 cells were subcutaneously inoculated
under the skin of the flank of female BALB/c nude mice. Once
the tumors were palpable (5 days after inoculation), (±)-25
(20 mg/kg) or vehicle control was administered ip once daily.
Tumors were measured twice weekly, and the well-being of
mice was assessed by measuring the body weight and
monitoring behavior. (±)-25 was well tolerated, and the
body weight of (±)-25-treated mice did not differ significantly
when compared with that of vehicle-treated mice. No adverse
effects were observed, and all mice exhibited apparently normal
activity, feeding, and inquisitiveness. Daily administration of
(±)-25 (20 mg/kg) significantly decreased breast cancer
xenograft tumor growth by 47% (Figure 4b; p < 0.001), 4
weeks after treatment.
■ CONCLUSIONS
Here, we report a systematic and extensive structure−activity
relationship study of our first-in-class AM2 receptor small
molecule antagonists.34 Through the careful optimization of
CLR and RAMP domain-binding fragments, we have been able
to develop a family of antagonists that show high selectivity for
AM2 over the closely related AM1 heteromer, by exploiting
Figure 3. Docking of compound (R)-25 in our pseudo (hybrid)-model of the AM2 receptor-binding pocket. Glu74 residues from RAMP3 are
indicated in green. CLR is shown in yellow and RAMP3 in cyan. Hydrogen bonds are shown as dotted lines. The protonated amine of compound
(R)-25 forms salt bridges with the carboxylate of Glu74 and the carboxylate of Asp71 (an asparagine carboxamide in RAMP3).
Figure 4. AM2 receptor antagonist inhibits in vitro viability of human breast cancer cell line MDA-MB-231 as well as subcutaneous MDA-MB-231
tumor growth in BALB/c nude mice. (a) Daily treatment with small molecule AM2 receptor antagonists significantly decreased the viability of
MDA-MB-231 cells in vitro by 55% after 3 days when treated with 10 μM (±)-25, compared to that of vehicle-treated controls (p < 0.01, unpaired
t-test). Data are from three independent experiments and presented as mean ± SD. (b) Mice (n = 10 per group) were inoculated subcutaneously
with MDA-MB-231 cells to generate tumors, and first treatment was given on the day of the first tumor volume measurement (arrow). Tumor
growth rates were significantly reduced in mice treated daily with 20 mg/kg ip (±)-25 (p < 0.001, simple linear regression comparing the line of
best fit). Data are presented as mean ± SD.
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differences in the RAMP structures, focusing on residues 70
and 84. A robust chemistry strategy allowed us to prepare a
large library of analogues and led to numerous derivatives with
nanomolar potencies. In addition, the products are readily
generated as single enantiomers through the employment of an
efficient asymmetric synthesis of the (R)-CLR-binding unit.
While our original goal was to identify compounds with
selectivity for AM2 receptors over all of the CLR and CTR
family receptors, we found it hard to separate AM2 and CGRP
receptors in this respect. However, since CGRP receptors
mediate pain, particularly bone pain in metastatic cancers, this
may be an additional benefit for therapy in oncology. Finally,
although we have previously shown the full drug-like properties
(ADME, hERG, and PK) and selectivity profile of compound
25 and the effects of this compound class in pancreatic cancer
cell viability and apoptosis in both in vitro and in vivo tumor
growth models,34 we demonstrate here that similar potent
antitumor effects are also observed in breast cancer models
using the highly aggressive triple-negative breast cancer cell
line MDA-MB-231.
■ EXPERIMENTAL SECTION
All reagents, unless otherwise stated, were obtained from commercial
sources and used without further purification. Small molecule
antagonists were prepared as 2 mM dimethyl sulfoxide (DMSO)
stocks for cell culture experiments and stored at −20 °C. Based on
each cell line’s ligand−receptor combination, the appropriate
unlabeled peptide was used. Human CGRP was obtained from
Sigma-Aldrich (SCP0060), and human AM was purchased from
Anaspec (AS-60447).
Chemical Methods. 1H NMR spectra were recorded on a Bruker
AVIII HD 400 (400 MHz), Bruker AVI 400 (400 MHz), Bruker
AMX-400 (400 MHz), or DPX-400 (400 MHz) supported by an
Aspect 3000 data system and referenced to the residual solvent peak
(CDCl3: δ 7.26 ppm). Signal positions were recorded in δ ppm with
the abbreviations s, d, t, q, br, and m denoting singlet, doublet, triplet,
quartet, broad, and multiplet, respectively. 19F NMR spectra were
recorded on a Bruker AVIII HD 400 (377 MHz) and are uncorrected.
Flash chromatography was performed on silica gel (BDH Silica Gel 60
43-60 or Fluorochem Davisil silica gel 43-60) using head pressure by
means of a compressed air line. Thin-layer chromatography (TLC)
was performed on commercially available precoated aluminum-backed
plates (Merck silica Kieselgel 60 F254). Spots were made visible
either by the quenching of UV fluorescence or by staining with a
potassium permanganate solution. All reactions were conducted in an
oven or flame-dried glassware under an inert atmosphere of dry
nitrogen or argon. Low-resolution mass spectra were (LC-MS)
recorded on Micromass Autospec, operating in E.I., C.I., or FAB
mode, or a PerkinElmer Turbomass Bench top GCMS operating in
either E.I. or C.I. mode. All ultraperformance liquid chromatography-
mass spectroscopy (UPLC-MS) analyses were carried out using
Waters Acquity UPLC-MS (quaternary pump flow 0.8 mL/min,
Acquity autosampler, PDA and QDA). All solvents, substrates, and
reagents that were commercially available were used without further
purification. Enantioselectivities were determined by high-perform-
ance liquid chromatography (HPLC) analysis employing a Gilson
HPLC chain with an ABI Analytical Spectroflow 783 UV or an SPD-
10 Shimadzu UV−vis detector. Purities of all final reported
compounds were greater than 95% based on analytical HPLC
chromatograms. Purification of the final compounds by preparative
HPLC was accomplished on a C18 250 mm × 21 mm column in
water/acetonitrile or with Biotage Isolera using a C18 Ultra cartridge
in water/acetonitrile with pH = 10 buffer followed by freeze-drying of
the pooled fractions containing pure products (Scheme 3).
N-Benzyl-N-(2-oxo-2-(4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]-
pyridin-1-yl)piperidin-1-yl)ethyl)pivalamide (2). 2A (12 mg, 0.047
mmol), 2B (13 mg, 0.052 mmol), and HATU (20 mg, 0.053 mmol)
were dissolved in dry DMF (2 mL). N-Methylmorpholine (0.1 mL,
1.75 mmol) was added, and the mixture was stirred at rt for 5 min.
The mixture was diluted with ethyl acetate and then washed with
brine, dried over magnesium sulfate, filtered, and the filtrate was
evaporated. The crude was purified using a Biotage Isolera (12 g, C18
Ultra cartridge, 60−80% acetonitrile/water with pH 10 buffer) and
freeze-dried to provide 2 as a white solid (14.3 mg, 68%). 1H NMR
(CD3OD, 300 MHz) δ 1.38 (s, 9H), 2.12 (br, 4H), 3.10−3.22 (m,
1H), 3.48−3.59 (m, 1H), 3.85 (br, 2H), 4.25−4.39 (m, 1H), 4.48−
4.58 (m, 1H), 4.72−4.83 (m, 1H), 5.06 (br, 2H), 6.90 (d, J = 7.5 Hz,
1H), 7.10 (t, J = 7.7 Hz, 1H), 7.25−7.34 (m, 4H), 7.35−7.43 (m,
2H); LC-MS [M + H]+ 450.
N-Benzyl-N-(2-oxo-2-(4-(2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-
piperidin-1-yl)ethyl)pivalamide (4). 2A (12.5 mg, 0.05 mmol), 2B
(15 mg, 0.06 mmol), and HATU (23 mg, 0.06 mmol) were dissolved
in dry DMF (2 mL). N-Methylmorpholine (0.1 mL, 1.75 mmol) was
added, and the mixture was stirred at rt for 5 min. The mixture was
diluted with ethyl acetate, washed with brine, dried over magnesium
sulfate, filtered, and the filtrate was evaporated. The crude was
purified using a Biotage Isolera (12 g, C18 Ultra cartridge, 60−80%
acetonitrile/water with pH 10 buffer) and freeze-dried to provide 2 as
a white solid (18.3 mg, 79%). 1H NMR (CD3OD, 300 MHz) δ 1.38
(s, 9H), 1.66−1.76 (m, 2H), 1.77−1.89 (m, 1H), 3.06−3.17 (m, 1H),
3.86−3.98 (m, 1H), 4.22 (br, 2H), 4.38 (s, 2H), 4.43−4.53 (m, 1H),
4.59−4.72 (m, 1H), 5.06 (br, 2H), 6.79 (d, J = 7.9 Hz, 1H), 6.94 (t, J
= 7.5 Hz, 1H), 7.11−7.17 (m, 1H), 7.26−7.34 (m, 4H), 7.36−7.43
(m, 2H); LC-MS [M + H]+ 463. (Scheme 4)
Ethyl 2-((Pyridin-2-ylmethyl)amino)acetate (5B) . (2-
Methylamino)pyridine 5A (6 g, 55.4 mmol) was dissolved in dry
THF (45 mL), and ethyl bromoacetate (4.63 g, 27.7 mmol) was
added dropwise at 0 °C. The mixture was stirred at rt for 2 h. The
reaction mixture was poured into water and extracted three times with
ethyl acetate. The organic layer was washed twice with ammonium
chloride, dried over sodium sulfate, filtered, and evaporated. The
residue was purified by flash chromatography (1:1 ethyl acetate/
heptane to 1:10 methanol/ethyl acetate) to provide 5B (1.43 g,
quantitative yield). (2.55 g, 47%) as an orange oil. UPLC-MS (short
basic) tR 1.30 (195 [M + H]+).
Ethyl 2-(N-(Pyridin-2-ylmethyl)pivalamido)acetate. 5B (1 g, 5.14
mmol) was dissolved in dichloromethane (30 mL) under an argon
atmosphere before trimethylamine (1.55 g, 15.42 mmol) was added.
Trimethylacetyl chloride (743 mg, 6.17 mmol) was added dropwise at
0 °C. The mixture was stirred at rt for 2 h after which the reaction was
shown to be complete by TLC. The mixture was poured into water,
and the aqueous layer was extracted three times with dichloro-
methane. The combined organic extracts were washed with brine,
dried over magnesium sulfate, filtered, and the filtrate was evaporated
to provide the crude product. The residue was purified by flash
chromatography (1:1−1:0 ethyl acetate/heptane) to provide ethyl 2-
(N-(pyridin-2-ylmethyl)pivalamido)acetate (1.45 g, quantitative
yield). UPLC-MS (short basic) tR 0.69 (279 [M + H]+).
2-(N-(Pyridin-2-ylmethyl)pivalamido)acetic Acid (5C). Ethyl 2-
(N-(pyridin-2-ylmethyl)pivalamido)acetate (1.45 g, 5.21 mmol) was
dissolved in THF (7 mL) and water (7 mL) and then lithium
Scheme 3. Synthesis of 2 and 4
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hydroxide monohydrate (655 mg, 15.62 mmol) was added, and the
mixture was stirred at rt for 16 h. The aqueous pH was again adjusted
to 6 and extracted with ethyl acetate (repeated 3 × 30 mL). The
organics were washed with brine, dried over magnesium sulfate,
filtered, and the filtrate was evaporated to provide 5C as a yellow oil
(871 mg, 67%). 1H NMR (DMSO-d6, 300 MHz) δ 1.15 (s, 9H), 3.32
(s, 2H), 4.75 (s, 2H), 7.49−7.61 (m, 1H), 7.81−7.92 (m, 1H), 8.51−
8.60 (m, 2H). UPLC-MS (short basic) tR 0.42 (251 [M + H]+).
N-(2-Oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-
pyrrolo[2,3-b]pyridin]-5-yl)amino)ethyl)-N-(pyridin-2-ylmethyl)-
pivalamide (5). 5C (50 mg, 0.20 mmol), 5D (50 mg, 0.20 mmol),
and HATU (75 mg, 0.20 mmol) were dissolved in dry DMF (2 mL).
N,N-Diisopropylethylamine (76 mg, 0.59 mmol) was added, and the
mixture was stirred at rt for 2 h. The mixture was diluted with ethyl
acetate (50 mL) and washed with brine (3 × 30 mL), dried over
magnesium sulfate, filtered, and the filtrate was evaporated. The crude
was purified on reverse phase chromatography to provide 5 as a white
solid (10.7 mg, 11%). 1H NMR (CD3OD, 300 MHz) δ 1.30 (s, 9H),
3.06 (dd, J = 15.8, 5.0 Hz, 2H), 3.50 (dd, J = 15.9, 7.9 Hz, 2H), 4.01
(s, 2H), 4.87 (s, 2H), 6.84−6.90 (m, 1H), 7.12 (d, J = 7.3 Hz, 1H),
7.23 (d, J = 8.0 Hz, 1H), 7.33−7.38 (m, 3H), 7.57 (s, 1H), 7.75−7.83
(m, 1H), 8.03 (dd, J = 5.3, 1.5 Hz, 1H), 8.44−8.49 (m, 1H). UPLC-
MS (short basic) tR 1.82 (484 [M + H]+).
Benzyl 2-(((1-Methylpiperidin-3-yl)methyl)amino)acetate (6B).
6A (0.5 g, 3.90 mmol) was dissolved in THF (10 mL), and
triethylamine (1.1 mL, 7.80 mmol) and benzylbromoacetate (0.61
mL, 3.90 mmol) were added. The mixture was stirred at rt for 60 h.
The mixture was poured into saturated sodium bicarbonate, and the
aqueous layer was extracted three times with dichloromethane. The
combined organic layers were dried over magnesium sulfate, filtered,
and evaporated. The residue was purified via flash silica chromatog-
raphy (19:1 dichloromethane/methanol) to provide 6B (318 mg,
30%). 1H NMR (CDCl3, 300 MHz) δ 0.80−0.97 (m, 1H), 1.40−1.91
(m, 6H), 2.24 (s, 3H), 2.40−2.55 (m, 2H), 2.75 (d, J = 11.1 Hz, 1H),
2.87 (d, J = 10.7 Hz, 2H), 3.43 (s, 2H), 5.16 (s, 2H), 7.29−7.40 (m,
5H). UPLC-MS (short basic) tR 1.81 (277 [M + H]+), 79% pure.
Benzyl 2-(N-((1-Methylpiperidin-3-yl)methyl)pivalamido)-
acetate. 6B (318 mg, 1.152 mmol) was dissolved in dichloromethane
(8 mL) under an argon atmosphere and triethylamine (0.19 mL,
1.382 mmol) was added, and the mixture was stirred at 5 °C (ice/
water). Trimethylacetyl chloride (0.14 mL, 1.152 mmol) was added
dropwise, and the mixture was stirred at rt for overnight. The reaction
mixture was diluted in dichloromethane, washed with brine, saturated
sodium bicarbonate, dried over magnesium sulfate, filtered, and the
filtrate was evaporated to provide the intermediate of 6C (344 mg,
83%). 1H NMR (DMSO-d6, 400 MHz) δ 0.91 (d, J = 8.0 Hz, 1H),
1.13 (s, 9H), 1.32−1.70 (m, 4H), 2.07 (s, 3H), 2.78−2.90 (m, 2H),
3.05−3.15 (m, 2H), 3.15−3.32 (m, 2H), 4.12 (s, 2H), 5.10 (s, 2H),
7.25−7.37 (m, 5H). UPLC-MS (short basic) tR 2.06 (361 [M + H]+),
88% pure.
2-(N-((1-Methylpiperidin-3-yl)methyl)pivalamido)acetic Acid
(6C). An intermediate of 6C (344 mg, 0.955 mmol) was dissolved
in ethanol (10 mL), and palladium-on-carbon (10% wet, 34 mg) was
added, the vessel was sealed, and an atmosphere of hydrogen was
introduced at a 400 psi pressure. The mixture was stirred at rt
overnight. The reaction was filtered through celite, washed with
methanol, and the filtrate was evaporated to provide 6C as a clear
glass (240 mg, 93%). 1H NMR (DMSO-d6, 300 MHz) δ 0.88−1.02
(m,1H), 1.17 (s, 9H), 1.35−1.65 (m, 3H), 1.79−2.10 (m, 3H), 2.18
(s, 3H), 2.60 (d, J = 9.0 Hz, 2H), 3.22 (d, J = 7.0 Hz, 2H), 3.99 (s,
2H). UPLC-MS (short basic) tR 0.42 (271 [M + H]+).
N-((1-Methylpiperidin-3-yl)methyl)-N-(2-oxo-2-((2′-oxo-1,1′,2′,3-
tetrahydrospiro[indene-2,3′-pyrrolo[2,3-b]pyridin]-5-yl)amino)-
ethyl)pivalamide (6). 6C (53 mg, 0.119 mmol), EDCI·HCl (46 mg,
0.239 mmol), and HOAt (33 mg, 0.239 mmol) were dissolved in dry
DMF (1 mL). N,N-Diisopropylethylamine (110 μL, 0.597 mmol) and
6D (50 mg, 0.119 mmol) were added, and the mixture was stirred at
rt overnight. The reaction mixture was poured into saturated sodium
bicarbonate and extracted three times with ethyl acetate and brine,
dried over magnesium sulfate, filtered, and the filtrate was evaporated.
The crude was directly purified using a Biotage Isolera (18 g, C18
Ultra cartridge, 10−70% acetonitrile/water with pH 10 buffer) to
provide a crude compound. This was further purified via SP4 (12 g,
Scheme 4. Synthesis of 5, 6, 9−14, 16−21, 24, 25, and 29a
a(a) Ethyl bromoacetate, SIPEA, DMF, rt or benzyl bromoacetate, Et3N, THF, rt (from amine) or glycine ethyl ester hydrochloride, NaBH3CN,
MeOH, rt (fromaldehyde or ketone); (b) (i) PivCl, DIPEA, DCM, rt; (ii) 2.5 N NaOH, MeOH, rt; (c) D, HATU, NMM, DMF, rt or D, EDCl,
HOAt, DIPEA, DMF, rt; (d) H2, Pd/C, NH4COOH, MeOH, reflux; (e) TFA, DCM, rt or TsOH, MeOH, rt; (f) (i) pTsOH, acetone, rt; (ii)
MeNH2, HCl, DIPEA, Na2SO4, DCM, rt then NaBH(OAc)3, rt; (g) 20% Pd(PPh3)4, 1,3-dimethylbarbituric acid, DCM, 35 °C; (h) Zn(CN)2,
Pd(PPh3)4, DMF, 130 °C, MW; (j) H2, Raney-Ni, 2M NH3 in MeOH, 55 °C; (k) 4-benzyl-3,5-dimethyl-1H-pyrazole-1-carboximidamide
hydrochloride, 5 equiv, Et3N, MeCN/THF, MW, 90 °C; (m) (i) pTsOH, acetone, rt; (ii) NH4OAc, MeOH, reflux; then NaBH3CN, rt; (n) H2O2,
H2O, NaOH, DMSO, rt.
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C18 cartridge, 5−75% acetonitrile in water with 0.1% ammonium
hydroxide) to provide 6 (3.1 mg, 5%). 1H NMR (DMSO-d6, 300
MHz) δ 0.77−0.96 (m, 1H), 1.16 (s, 9H), 1.48−1.62 (m, 4H), 1.75−
1.92 (m, 2H), 2.08 (s, 3H), 2.47−2.59 (m, 2H), 2.97−3.00 (m, 2H),
3.23−3.31 (m, 2H), 4.19 (s, 2H), 6.84 (dd, J = 7.3, 5.3 Hz, 1H),
7.12−7.21 (m, 2H), 7.33 (d, J = 7.9 Hz, 1H), 7.54 (s, 1H), 8.03 (dd, J
= 5.3, 1.6 Hz, 1H), 9.97 (s, 1H), 11.08 (s, br, 1H). UPLC-MS (short
basic) tR 1.78 (504 [M + H]+).
tert-Butyl-2-((2-((1H-imidazol-1-yl)methyl)benzyl)amino)acetate
(19B). (2-((1H-Imidazol-1-yl)methyl)phenyl)methanamine dihydro-
chloride 19A (200 mg, 0.76 mmol) and N,N-diisopropylethylamine
(596 mg, 4.61 mmol) were dissolved in dry DMF (5 mL). A solution
of tert-butyl bromoacetate (135 mg, 0.69 mmol) in DMF (1 mL) was
added slowly. The mixture was stirred at rt for 18 h. The reaction
mixture was combined with another batch of material (0.192 mmol),
quenched with saturated aqueous ammonium chloride solution, and
extracted three times with ethyl acetate. The organic extracts were
dried over sodium sulfate, filtered, and evaporated to provide 19B
(100 mg, 22%) as a pale yellow solid that was used directly in the next
step. UPLC-MS (short basic) rt 0.58 (302 [M + H]+).
tert-Butyl-2-(N-(2-( (1H-imidazol-1-yl )methyl)benzyl)-
pivalamido)acetate. 19B (50 mg, 0.166 mmol) was dissolved in
dichloromethane (3 mL) under an argon atmosphere, and N,N-
diisopropylethylamine (43 mg, 0.332 mmol) was added. Trimethy-
lacetyl chloride (30 mg, 0.249 mmol) was added, and the mixture was
stirred at rt overnight. Further trimethylacetyl chloride (20 mg, 0.166
mmol) was added. UPLC indicated that the reaction was incomplete.
The mixture was quenched with saturated aqueous ammonium
chloride solution and extracted three times with dichloromethane.
The organic extracts were dried over sodium sulfate, filtered, and the
filtrate was evaporated. The residue was dissolved in pyridine (1 mL),
and trimethylacetyl chloride (96 mg, 0.797 mmol) was added. The
mixture was stirred at rt for 2 h and evaporated. The residue was
dissolved in water and extracted three times with ethyl acetate. The
organic extracts were dried over sodium sulfate, filtered, and the
filtrate was evaporated. The crude residue was purified via reverse
phase chromatography (30 g, C18 cartridge acetonitrile/pH 10 buffer
with ammonium bicarbonate) to provide the intermediate of 19C (80
mg, 83%) as a white solid that was used directly in the next step.
UPLC-MS (long basic) rt 2.02 (386 [M + H]+).
2-(N-(2-((1H-Imidazol-1-yl)methyl)benzyl)pivalamido)acetic
Acid (19C). An intermediate of 19C (80 mg, 0.207 mmol) was
dissolved in methanol (3 mL) and 2 M sodium hydroxide (0.311 mL,
0.622 mmol) was added, and the mixture was stirred at rt for 2 days.
The mixture was acidified to pH 5 with 2 M aqueous HCl solution
and extracted twice with ethyl acetate. The organic extracts were dried
over sodium sulfate, evaporated, filtered, and the filtrate was
evaporated to provide 19C (40 mg, 59%) as a white solid. 1H
NMR (CD3OD, 300 MHz) δ 1.29 (s, 9H), 3.98 (s, 2H), 4.72 (s, 2H),
5.25 (s, 2H), 6.92−7.03 (m, 2H), 7.17−7.27 (m, 2H), 7.22−7.43 (m,




amino)ethyl)pivalamide (19). 19C (40 mg, 0.121 mmol), EDCI·HCl
(25 mg, 0.182 mmol), and HOAt (35 mg, 0.182 mmol) were
dissolved in dry DMF (2 mL). N,N-Diisopropylethylamine (83 mg,
0.73 mmol) and 19D (37 mg, 0.147 mmol) were added, and the
mixture was stirred at rt for 18 h. The mixture was poured into
saturated ammonium chloride, and the aqueous layer was extracted
three times with ethyl acetate. The organic extract was washed three
times with sodium bicarbonate, dried over sodium sulfate, filtered, and
the filtrate was evaporated. The residue was purified via reverse phase
chromatography (SP4 30 g, C18 cartridge acetonitrile/pH 10 buffer
with ammonium bicarbonate) to provide 19 (16 mg, 24%) as a
colorless glass. 1H NMR (CD3OD, 300 MHz) δ 1.20 (s, br, 9H), 3.03
(d, J = 15.7 Hz, 2H), 3.48 (d, J = 15.9 Hz, 2H), 4.01 (s, br, 2H), 4.76
(s, 2H), 5.29 (s, 2H), 6.81−7.46 (m, 10H), 7.52 (s, 1H), 7.68 (s,
1H), 8.02 (d, J = 5.5 Hz, 1H). UPLC-MS (long basic) tR 1.87 (563
[M + H]+), 100% pure.
Ethyl 2-((2-(Hydroxymethyl)benzyl)amino)acetate (13B). 13A
(200 mg, 1.15 mmol) was dissolved in THF (2 mL) and dry DMF
(4 mL), and triethylamine (744 mg, 5.76 mmol) and ethyl
bromoacetate (173 mg, 1.04 mmol) were added. The mixture was
stirred at rt for 3 h. The mixture was poured into saturated sodium
bicarbonate, and the aqueous layer was extracted three times with
ethyl acetate. The combined organic layers were dried over
magnesium sulfate, filtered, and evaporated. The residue was purified
via reverse phase chromatography (SP4 30 g, C18 cartridge
acetonitrile/pH 10 buffer with ammonium bicarbonate) to provide
13B (200 mg, 52%). 1H NMR (CDCl3, 300 MHz) δ 1.27 (t, J = 7.1
Hz, 3H), 3.40 (s, 2H), 3.80 (s, 2H), 4.19 (q, J = 7.2 Hz, 2H), 4.69 (s,
2H), 7.22−7.37 (m, 4H). UPLC-MS (short basic) tR 0.62 (224 [M +
H]+).
Ethyl 2-(N-(2-(Hydroxymethyl)benzyl)pivalamido)acetate. 13B
(210 mg, 0.94 mmol) was dissolved in dichloromethane (10 mL)
and dry DMF (2 mL) under an argon atmosphere, N,N-
diisopropylethylamine (364 mg, 2.82 mmol) was added, and the
mixture was stirred at 5 °C (ice/water). Trimethylacetyl chloride (113
mg, 0.94 mmol) was added dropwise, and the mixture was stirred at rt
overnight. The reaction mixture was diluted in dichloromethane,
washed with brine and saturated ammonium chloride, dried over
magnesium sulfate, filtered, and the filtrate was evaporated. The
residue was purified via reverse phase chromatography (SP4 30 g, C18
cartridge acetonitrile/pH 10 buffer with ammonium bicarbonate) to
provide intermediate 13C (110 mg, 38%). UPLC-MS (short basic) tR
0.71 (308 [M + H]+).
2-(N-(2-(Hydroxymethyl)benzyl)pivalamido)acetic Acid (13C).
Intermediate 13C (110 mg, 0.36 mmol) was dissolved in THF (3
mL). Methanol (3 mL) and lithium hydroxide monohydrate (45 mg,
1.07 mmol) were added, and the mixture was stirred at rt for 3 h. The
pH was adjusted carefully to 4 by the addition of 2 M HCl and
extracted with ethyl acetate. The volatiles were removed, and the
residue was purified via reverse phase chromatography (SP4 30 g, C18
cartridge acetonitrile/pH 10 buffer with ammonium bicarbonate) to
provide 13C (60 mg, 60%). 1H NMR (CD3OD, 300 MHz) δ 1.24 (s,
9H), 3.86 (s, br, 2H), 4.61 (s, 2H), 4.90 (s, 2H), 7.00−7.30 (m, 4H).
UPLC-MS (short basic) tR 0.44 (280 [M + H]+).
N-(2-(Hydroxymethyl)benzyl)-N-(2-oxo-2-((2′-oxo-1,1′,2′,3-
tetrahydrospiro[indene-2,3′-pyrrolo[2,3-b]pyridin]-5-yl)amino)-
ethyl)pivalamide (13). 13C (60 mg, 0.21 mmol), EDCI·HCl (62 mg,
0.32 mmol), and HOAt (44 mg, 0.32 mmol) were dissolved in dry
DMF (4 mL). N,N-Diisopropylethylamine (83 mg, 0.64 mmol) and
13D (54 mg, 0.21 mmol) were added, and the mixture was stirred at
rt overnight. The mixture was poured into saturated ammonium
chloride, and the aqueous layer was extracted twice with ethyl acetate.
The organic extract was dried over sodium sulfate, filtered, and the
filtrate was evaporated. The residue was purified via reverse phase
chromatography (SP4 30 g, C18 cartridge acetonitrile/pH 10 buffer
with ammonium bicarbonate) to provide 13 (25 mg, 23%). 1H NMR
(CD3OD, 400 MHz) δ 1.32 (s, 9H), 2.95 (dd, J = 15.6, 10.6 Hz, 2H),
3.51 (dd, J = 15.8, 7.5 Hz, 2H), 4.09 (s, 2H), 4.63 (s, 2H), 5.00 (s, br,
2H), 6.74−6.83 (m, 1H), 7.07 (dd, J = 16.4, 7.6 Hz, 1H), 7.15−7.37
(m, 6H), 7.46 (s, 1H), 8.07 (s, 1H), 8.87 (s, 1H). UPLC-MS (long
basic) tR 1.83 (513 [M + H]+).
Ethyl 2-((2-(Morpholinomethyl)benzyl)amino)acetate. 18A (100
mg, 0.48 mmol) was dissolved in dry DMF (2.5 mL) and N,N-
diisopropylethylamine (0.47 mL, 2.58 mmol). Ethyl bromoacetate (72
mg, 0.43 mmol) was added dropwise at 0 °C. The mixture was stirred
at rt for 5 h. The reaction mixture was poured into water and
extracted three times with ethyl acetate. The organic layer was washed
twice with ammonium chloride, dried over sodium sulfate, filtered,
and evaporated to provide 18B (70 mg) that was used directly in the
next step. UPLC-MS (short basic) tR 0.73 (293 [M + H]+).
Ethyl 2-(N-(2-(Morpholinomethyl)benzyl)pivalamido)acetate.
18B (70 mg, 0.24 mmol) was dissolved in dichloromethane (3 mL)
under an argon atmosphere and then N,N-diisopropylethylamine (62
mg, 0.48 mmol) was added, and the mixture was stirred at 5 °C (ice/
water). Trimethylacetyl chloride (110 μL, 0.89 mmol) was added
dropwise, and then the mixture was stirred at rt over the weekend.
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The reaction mixture was diluted in dichloromethane, washed with
brine and saturated ammonium chloride, dried over magnesium
sulfate, filtered, and the filtrate was evaporated. The residue was
purified via reverse phase chromatography (SP4 30 g, C18 cartridge
acetonitrile/pH 10 buffer with ammonium bicarbonate) to provide
the intermediate of 18C (40 mg, 44%). UPLC-MS (short basic) tR
0.87 (377 [M + H]+).
2-(N-(2-(Morpholinomethyl)benzyl)pivalamido)acetic Acid. An
intermediate of 18C (40 mg, 0.17 mmol) was dissolved in methanol
(2 mL) and 2.0 M sodium hydroxide (159 μL, 0.318 mmol) was
added, and the mixture was stirred at rt overnight. The volatiles were
removed, and then the residue was dissolved in water. The pH was
adjusted carefully to 4 by the addition of 2 M HCl, and the crude
material was extracted with ethyl acetate. The aqueous pH was again
adjusted to 4, and the product was extracted with ethyl acetate. The
organics were washed with brine, dried over magnesium sulfate,
filtered, and the filtrate was evaporated to provide 18C (59 mg,
quant.) that was used directly in the next step. UPLC-MS (short
basic) tR 0.50 (349 [M + H]+).
N-(2-(Morpholinomethyl)benzyl)-N-(2-oxo-2-((2′-oxo-1,1′,2′,3-
tetrahydrospiro[indene-2,3′-pyrrolo[2,3-b]pyridin]-5-yl)amino)-
ethyl)pivalamide (18). 18C (40 mg, 0.11 mmol), EDCI·HCl (33 mg,
0.17 mmol), and HOAt (22 mg, 0.17 mmol) were dissolved in dry
DMF (3 mL). N,N-Diisopropylethylamine (89 mg, 0.68 mmol) and
18D (35 mg, 0.14 mmol) were added, and the mixture was stirred at
rt for 5 h. The mixture was poured into saturated ammonium
chloride, and the aqueous layer was extracted twice with ethyl acetate.
The organic extract was dried over sodium sulfate, filtered, and the
filtrate was evaporated. The residue was purified via reverse phase
chromatography (SP4 30 g, C18 cartridge acetonitrile/pH 10 buffer
with ammonium bicarbonate) to provide 18 (44 mg, 66%). 1H NMR
(CD3OD, 300 MHz) δ 1.32 (s, 9H), 2.38 (s, br, 4H), 3.05 (dd, J =
15.8, 5.6 Hz, 2H), 3.48 (dd, J = 15.6, 10.5 Hz, 2H), 3.52−3.61 (m,
4H), 4.05 (s, 2H), 5.21 (s, 2H), 6.86 (dd, J = 7.4, 5.4 Hz, 1H), 7.10
(dd, J = 7.4, 1.6 Hz, 1H), 7.17−7.25 (m, 4H), 7.32 (s, br, 1H), 7.37
(d, J = 8.4 Hz, 1H), 7.55 (s, 1H), 8.03 (dd, J = 5.4, 1.6 Hz, 1H).
UPLC-MS (long basic) tR 2.27 (582 [M + H]+).
(2-(1-Benzylpyrrolidin-3-yl)phenyl)methanamine (9A). NaBH4
(0.75 g, 20 mmol) was carefully added to a solution of the
corresponding nitrile 9E (1 g, 3.82 mmol) and CoCl2 (25 mg, 0.19
mmol) in methanol (40 mL) at room temperature. The mixture was
stirred at rt for 4 h. The reaction mixture was slowly quenched with
saturated ammonium chloride (4 mL), diluted with ethyl acetate, and
filtered through celite. The aqueous layer was extracted three times
with ethyl acetate. The organic layer was washed with ammonium
chloride, dried over sodium sulfate, filtered, and evaporated. The
crude was purified using a Biotage Isolera (18 g, C18 Ultra cartridge,
30−60% acetonitrile/water with pH 10 buffer) to provide 9A (356
mg, 35%). UPLC-MS (short basic) tR 0.48 (267 [M + H]+).
Ethyl 2-((2-(1-Benzylpyrrolidin-3-yl)benzyl)amino)acetate (9B).
9A (40 mg, 0.15 mmol) was dissolved in dry DMF (2 mL), and
triethylamine (74 mg, 0.57 mmol) and ethyl bromoacetate (27 mg,
0.16 mmol) were added. The mixture was stirred at rt overnight. The
mixture was poured into saturated sodium bicarbonate, and the
aqueous layer was extracted three times with ethyl acetate. The
organic layer was washed twice with ammonium chloride, dried over
sodium sulfate, filtered, and evaporated to provide 9B (63 mg).
UPLC-MS (short basic) tR 0.62 (353 [M + H]+).
Ethyl 2-(N-(2-(1-Benzylpyrrolidin-3-yl)benzyl)pivalamido)-
acetate. 9B (63 mg, 0.178 mmol) was dissolved in dichloromethane
(3 mL) under an argon atmosphere and N,N-diisopropylethylamine
(0.40 μL, 0.45 mmol) was added, and the mixture was stirred at 5 °C
(ice/water). Trimethylacetyl chloride (25 μL, 0.20 mmol) was added
dropwise, and the mixture was stirred at rt for 4 h. The reaction
mixture was diluted in dichloromethane, washed with brine and
saturated sodium bicarbonate, dried over magnesium sulfate, filtered,
and the filtrate was evaporated. The residue was purified via flash
silica chromatography (5:1−1:1 heptane/EtOAc) to provide methyl
2-(N-(2-(1-benzylpyrrolidin-3-yl)benzyl)pivalamido)acetate (52 mg,
67%). UPLC-MS (short basic) tR 1.05 (437 [M + H]+).
2-(N-(2-(1-Benzylpyrrolidin-3-yl)benzyl)pivalamido)acetic Acid
(9C). Methyl 2-(N-(2-(1-benzylpyrrolidin-3-yl)benzyl)pivalamido)-
acetate (52 mg, 0.13 mmol) was dissolved in a mixture of methanol
(2 mL), tetrahydrofuran (2 mL), and water (1 mL), and lithium
hydroxide monohydrate (16 mg, 0.65 mmol) was added. The reaction
mixture was stirred overnight before the pH was adjusted carefully to
4 by the addition of 2 M HCl and volatiles were removed. The crude
product was directly purified via flash silica chromatography (5−30%
methanol/dichloromethane) to provide the desired 9C as a colorless
solid (50 mg, 95%). UPLC-MS (short basic) tR 0.51 (409 [M + H]+).
N-(2-(1-Benzylpyrrolidin-3-yl)benzyl)-N-(2-oxo-2-((2′-oxo-
1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-b]pyridin]-5-yl)-
amino)ethyl)pivalamide (9F). 9C (50 mg, 0.12 mmol), 9D (30 mg,
0.12 mmol), and HATU (54 mg, 0.14 mmol) were dissolved in dry
DMF (2.5 mL). N-Methylmorpholine (0.25 mL) was added, and the
mixture was stirred at room temperature for 10 min. The mixture was
diluted with ethyl acetate and washed with brine, dried over
magnesium sulfate, filtered, and the filtrate was evaporated. The
residue was purified via flash silica chromatography (70−100% ethyl
acetate/petrol ether) to provide 9F (64 mg, 83%) as a colorless glass.
1H NMR (CDCl3, 400 MHz) δ 1.30 (s, 9H), 1.76−1.85 (m, 1H),
2.30−2.39 (m, 1H), 2.62−2.79 (m, 3H), 2.91 (t, J = 8.6 Hz, 1H),
3.03 (dd, J = 15.8, 6.2 Hz, 2H), 3.45−3.51 (m, 1H), 3.56−3.73 (m,
4H), 4.03 (s, 2H), 4.93 (s, 2H), 6.80 (dd, J = 7.1, 5.5 Hz, 1H), 7.02−
7.07 (m, 2H), 7.15−7.37 (m, 8H), 7.48 (d, J = 7.6 Hz, 1H), 7.52 (s,
1H), 8.11 (d, J = 5.3, 1.5 Hz, 1H), 8.43 (s, 1H). UPLC-MS (short
basic) tR 0.91 (642 [M + H]+), 99% pure.
N-(2-Oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-
pyrrolo[2,3-b]pyridin]-5-yl)amino)ethyl)-N-(2-(pyrrolidin-3-yl)-
benzyl)pivalamide (9). 9F (59 mg, 0.09 mmol) and Pd/C (10 mg)
were dissolved in methanol (5 mL) followed by the addition of
NH4COOH (57 mg, 0.9 mmol), and the mixture was refluxed for 4 h.
The reaction mixture was diluted with ethyl acetate and filtered. The
solvent was evaporated under reduced pressure, and the residue was
purified (500 mg SCX-2 MeOH to ammonia in MeOH) to provide 9
(28 mg, 55%) as a colorless solid. 1H NMR (CD3OD, 300 MHz) δ
1.33 (s, 9H), 2.02−2.15 (m, 1H), 2.32−2.43 (m, 1H), 3.00−3.12 (m,
3H), 3.14−3.25 (m, 1H), 3.30−3.38 (m, 1H), 3.40−3.59 (m, 3H),
3.61−3.76 (m, 2H), 4.17 (s, 2H), 4.90 (br s, 2H), 6.87 (d, J = 7.3, 5.4
Hz, 1H), 7.12 (dd, J = 7.4, 1.3 Hz, 1H), 7.17−7.24 (m, 2H), 7.28−
7.38 (m, 3H), 7.40−7.45 (m, 1H), 7.51−7.55 (m, 1H), 8.02 (dd, J =
5.3, 1.4 Hz, 1H). UPLC-MS (short basic) tR 0.66 (552 [M + H]+),
97% pure.
Ethyl 2-((3-(((tert-Butoxycarbonyl)amino)methyl)benzyl)amino)-
acetate (14B). 14A (150 mg, 0.635 mmol) was dissolved in THF (4
mL), and triethylamine (0.13 mL, 0.825 mmol) and ethyl
bromoacetate (63 μL, 0.571 mmol) were added. The mixture was
stirred at rt for 2 h. The mixture was poured into saturated sodium
bicarbonate, and the aqueous layer was extracted three times with
ethyl acetate. The combined organic layers were dried over
magnesium sulfate, filtered, and evaporated. The residue was purified
via reverse phase chromatography (SP4 30 g, C18 cartridge
acetonitrile/pH 10 buffer with ammonium bicarbonate) to provide
14B (90 mg, 44%). 1H NMR (CD3OD, 300 MHz) δ 1.24 (t, J = 7.1
Hz, 3H), 1.44 (s, 9H), 3.33 (s, 2H), 3.74 (s, 2H), 4.16 (q, J = 6.9 Hz,
2H), 4.21 (s, 2H), 7.15−7.31 (m, 4H). UPLC-MS (short basic) tR
0.73 (323 [M + H]+).
Ethyl 2-(N-(3-(((tert-Butoxycarbonyl)amino)methyl)benzyl)-
pivalamido)acetate. 14B (90 mg, 0.279 mmol) was dissolved in
dichloromethane (2 mL) under an argon atmosphere and N,N-
diisopropylethylamine (0.72 μL, 0.42 mmol) was added, and the
mixture was stirred at 5 °C (ice/water). Trimethylacetyl chloride (34
μL, 0.28 mmol) was added dropwise, and the mixture was stirred at rt
over the weekend. The reaction mixture was diluted in dichloro-
methane, washed with brine and saturated sodium bicarbonate, dried
over magnesium sulfate, filtered, and the filtrate was evaporated. The
residue was purified via flash silica chromatography (1:1 heptane/
EtOAc) to provide ethyl 2-(N-(3-(((tert-butoxycarbonyl)amino)-
methyl)benzyl)pivalamido)acetate (95 mg, 84%). LC-MS tR 2.19
(407 [M + H]+).
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2-(N-(3-(((tert-Butoxycarbonyl)amino)methyl)benzyl)-
pivalamido)acetic Acid (14C) . Ethyl 2-(N -(3-((( ter t -
butoxycarbonyl)amino)methyl)benzyl)pivalamido)acetate (95 mg,
0.234 mmol) was dissolved in THF (1 mL) and methanol (1 mL),
and lithium hydroxide monohydrate (15 mg, 0.351 mmol) was added
and the mixture was stirred at rt overnight. The pH was adjusted
carefully to 4 by the addition of 2 M HCl, and the product was
extracted with dichloromethane. The volatiles were removed to
provide 14C (76 mg, 80%). 1H NMR (CDCl3, 300 MHz) δ 1.32 (s,
9H), 1.44 (s, 9H), 3.91 (s, br, 2H), 4.20−4.33 (m, 2H), 4.80 (s, 2H),
4.97−5.06 (m, 1H), 7.06−7.10 (m, 2H), 7.15−7.23 (d, 1H), 7.27−
7.35 (m, 1H). LC-MS tR 1.54 (379 [M + H]+).
tert-Butyl 3-((N-(2-Oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro-
[indene-2,3′-pyrrolo[2,3-b]pyridin]-5-yl)amino)ethyl)pivalamido)-
methyl)benzylcarbamate (14E). 14C (71 mg, 0.188 mmol), EDCI·
HCl (43 mg, 0.226 mmol), and HOAt (30 mg, 0.226 mmol) were
dissolved in dry DMF (2 mL). N,N-Diisopropylethylamine (0.11 mL,
0.678 mmol) and 14D (47 mg, 0.188 mmol) were added, and the
mixture was stirred at rt overnight. The mixture was diluted with ethyl
acetate and washed with saturated sodium bicarbonate. The aqueous
layer was extracted twice with ethyl acetate. The combined organics
were washed three times with water and then with brine, dried over
magnesium sulfate, filtered, and the filtrate was evaporated. The
residue was purified via flash silica chromatography (5% methanol/
dichloromethane) to provide 14E (60 mg, 52%). 1H NMR (CDCl3,
400 MHz) δ 1.37 (s, 9H), 1.45 (s, 9H), 3.03 (dd, J = 15.7, 5.7 Hz,
2H), 3.60 (dd, J = 15.8, 6.0 Hz, 2H), 3.99 (s, 2H), 4.28 (d, J = 5.5 Hz,
2H), 4.81−4.91 (m, 2H), 6.81 (dd, J = 7.3, 5.3 Hz, 1H), 7.06 (dd, J =
7.3, 1.3 Hz, 1H), 7.10−7.23 (m, 5H), 7.32 (t, J = 7.8 Hz, 1H), 7.52 (s,
1H), 8.11 (d, J = 5.3, 1.5 Hz, 1H), 8.40−8.46 (m, 2H). UPLC-MS
(long basic) tR 2.36 (612 [M + H]+), 96% pure.
N-(3-(Aminomethyl)benzyl)-N-(2-oxo-2-((2′-oxo-1,1′,2′,3-
tetrahydrospiro[indene-2,3′-pyrrolo[2,3-b]pyridin]-5-yl)amino)-
ethyl)pivalamide (14). 14E (30 mg, 0.049 mmol) was dissolved in
methanol (2 mL), and p-toluene sulfonic acid monohydrate (19 mg,
0.10 mmol) was added. The mixture was stirred at 50 °C for 3.5 h and
poured into saturated sodium bicarbonate. The aqueous layer was
extracted with ethyl acetate. The organic extract was washed with
brine, dried over magnesium sulfate, filtered, and the filtrate was
evaporated. The residue was purified via SPE (2 g SiO2, EtOAc and
then 10% MeOH in DCM) to provide 14 (5 mg, 20%). 1H NMR
(CD3OD, 300 MHz) δ 1.34 (s, 9H), 3.05 (dd, J = 15.9, 3.7 Hz, 2H),
3.49 (dd, J = 15.6, 7.5 Hz, 2H), 3.88 (s, 2H), 4.06 (s, br, 2H), 4.88 (s,
br, 2H), 6.87 (dd, J = 7.1, 1.5 Hz, 1H), 7.12 (d, J = 7.3 Hz, 1H), 7.21
(d, J = 8.0 Hz, 2H), 7.26−7.39 (m, 4H), 7.52 (s, 1H), 8.03 (d, J = 5.5
Hz, 1H). LC-MS tR 4.98 (512 [M + H]+), 95% pure.
Methyl 2-(((1H-Indazol-4-yl)methyl)amino)acetate (10B). 10A
(124 mg, 0.85 mmol) was dissolved in methanol (2.5 mL), and then
methyl glycinate hydrochloride (320 mg, 2.52 mmol) and sodium
cyanoborohydride (80 mg, 1.27 mmol) were added and the mixture
was stirred at rt over the weekend. The reaction mixture was poured
into water, and the pH was adjusted to 4 with 2 M HCl and washed
twice with dichloromethane. The aqueous layer was basified with
sodium carbonate and extracted twice with dichloromethane. This
organic extract was dried over magnesium sulfate, filtered, and
evaporated. The residue was purified by Isolera (acetonitrile/
NH4COOH buffer pH = 10) to provide 10B (35 mg, 19%).
UPLC-MS (short basic) tR 1.46 (220 [M + H]+).
Methyl 2-(N-((1H-Indazol-4-yl)methyl)pivalamido)acetate. 10B
(35 mg, 0.15 mmol) was dissolved in dichloromethane (2 mL) and
tetrahydrofuran (2 mL) under an argon atmosphere, and N,N-
diisopropylethylamine (0.08 mL, 0.5 mmol) was added and the
mixture was stirred at 5 °C (ice/water). Trimethylacetyl chloride (20
μL, 0.16 mmol) was added dropwise, and the mixture was stirred at rt
over the weekend. The reaction mixture was diluted in dichloro-
methane, washed with brine and saturated ammonium chloride, dried
over magnesium sulfate, filtered, and the filtrate was evaporated to
provide crude methyl 2-(N-((1H-indazol-4-yl)methyl)pivalamido)-
acetate (60 mg, 124%) that was used directly in the next step. UPLC-
MS (short basic) tR 0.66 (302 [M + H]+).
2-(N-((1H-Indazol-4-yl)methyl)pivalamido)acetic Acid. Methyl 2-
(N-((1H-indazol-4-yl)methyl)pivalamido)acetate (60 mg, 0.20
mmol) was dissolved in methanol (2.2 mL), and 2.5 M sodium
hydroxide (0.12 mL, 0.30 mmol) was added and the mixture was
stirred at rt over the weekend. The volatiles were removed, and the
residue was dissolved in water. The pH was adjusted carefully to 4 by
the addition of 2 M HCl and extracted with ethyl acetate. The
aqueous pH was again adjusted to 4 and extracted with ethyl acetate.
The organics were washed with brine, dried over magnesium sulfate,
filtered, and the filtrate was evaporated to provide 10C (49 mg, 86%)
that was used directly in the next step. UPLC-MS (short basic) tR




ethyl)pivalamide (10). 10C (35 mg, 0.12 mmol), EDCI·HCl (32 mg,
0.16 mmol), and HOAt (27 mg, 0.20 mmol) were dissolved in dry
DMF (1.1 mL). N,N-Diisopropylethylamine (62 μL, 0.63 mmol) and
10D (29 mg, 0.12 mmol) were added, and the mixture was stirred at
rt overnight. The mixture was poured into saturated ammonium
chloride, and the aqueous layer was extracted twice with ethyl acetate.
The organic extract was dried over sodium sulfate, filtered, and the
filtrate was evaporated. The crude was directly purified using a
Biotage Isolera (12 g, C18 Ultra cartridge, 20−40% acetonitrile/water
with pH 10 buffer) to provide crude 10 (31 mg, 49%) as a colorless
solid. 1H NMR (CD3OD, 300 MHz) δ 1.24 (s, 9H), 3.03 (dd, J =
16.0, 10.7 Hz, 2H), 3.30 (dd, J = 16.0, 9.2 Hz, 2H), 4.04 (s, 2H), 5.02
(s, 2H), 6.82 (dd, J = 7.3, 5.3 Hz, 1H), 6.90 (d, J = 6.9 Hz, 1H),
7.10−7.55 (m, 7H), 8.00−8.05 (m, 2H), 9.75 (s, 1H), 10.94 (s, 1H).
UPLC-MS (long basic) tR 1.81 (523 [M + H]+), 100% pure.
Methyl 2-((2-(Pyridin-3-yl)benzyl)amino)acetate (20B). 20A (629
mg, 3.34 mmol) was dissolved in methanol (9.8 mL), and then methyl
glycinate hydrochloride (1.3 g, 10.3 mmol) and sodium cyanobor-
ohydride (324 mg, 5.1 mmol) were added and the mixture was stirred
at rt overnight. The reaction mixture was poured into water and the
pH was adjusted to 4 with 2 M HCl and then washed twice with
dichloromethane. The aqueous layer was basified with sodium
carbonate and extracted twice with dichloromethane. This organic
extract was dried over magnesium sulfate, filtered, and evaporated to
provide 20B (410 mg, 48%) as a colorless oil. UPLC-MS (short
basic) tR 0.62 (257 [M + H]+), 96% pure.
Methyl 2-(N-(2-(Pyridin-3-yl)benzyl)pivalamido)acetate. 20B (97
mg, 0.38 mmol) was dissolved in dichloromethane (4 mL) under an
argon atmosphere, and N,N-diisopropylethylamine (0.2 mL, 1.1
mmol) was added and the mixture was stirred at 5 °C (ice/water).
Trimethylacetyl chloride (56 μL, 0.45 mmol) was added dropwise,
and the mixture was stirred at rt overnight. The reaction mixture was
diluted in dichloromethane, washed with brine and saturated sodium
bicarbonate, dried over magnesium sulfate, filtered, and the filtrate
was evaporated. The residue was purified via flash silica chromatog-
raphy (0:1−1:10 MeOH/EtOAc) to provide methyl 2-((2-(pyridin-3-
yl)benzyl)amino)acetate (22 mg, 17%). UPLC-MS (short basic) tR
0.74 (341 [M + H]+).
2-(N-(2-(Pyridin-3-yl)benzyl)pivalamido)acetic Acid (20C). Meth-
yl 2-((2-(pyridin-3-yl)benzyl)amino)acetate (22 mg, 0.06 mmol) was
dissolved in methanol (1 mL), and 2.5 M sodium hydroxide (0.2 mL,
0.50 mmol) was added and the mixture was stirred at rt overnight.
The volatiles were removed, and then the residue was dissolved in
water. The pH was adjusted carefully to 4 by the addition of 2 M HCl
and extracted with ethyl acetate. The aqueous pH was again adjusted
to 4. The aqueous layer was extracted with dichloromethane
(repeated three times). The organics were washed with brine, dried
over magnesium sulfate, filtered, and the filtrate was evaporated to
provide 20C as a yellow oil that was used directly in the next step (8
mg, 38%). UPLC-MS (short basic) tR 0.49 (327 [M + H]+).
N-(2-Oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-
pyrrolo[2,3-b]pyridin]-5-yl)amino)ethyl)-N-(2-(pyridin-3-yl)benzyl)-
pivalamide (20). 20C (8 mg, 0.02 mmol), EDCI·HCl (7 mg, 0.03
mmol), and HOAt (5 mg, 0.08 mmol) were dissolved in dry DMF
(0.5 mL). N,N-Diisopropylethylamine (13 μL, 0.07 mmol) and 20D
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(7 mg, 0.03 mmol) were added, and the mixture was stirred at rt
overnight. The crude was directly purified via MDAP (XBridge C18
19 × 150, 30−60% acetonitrile water with 0.1% ammonium
hydroxide) to provide 20 (8 mg, 38%) as a pale yellow solid. 1H
NMR (CDCl3, 300 MHz) δ 1.30 (s, 9H), 3.01 (dd, J = 15.8, 2.0 Hz,
2H), 3.59 (dd, J = 15.8, 2.8 Hz, 2H), 4.00 (s, 2H), 4.78 (s, 2H), 6.80
(dd, J = 7.3, 5.3 Hz, 1H), 7.05 (dd, J = 7.4, 1.5 Hz, 1H), 7.14−7.17
(m, 2H), 7.24−7.31 (m, 2H), 7.36−7.47 (m, 4H), 7.68 (dt, J = 7.9,
1.9 Hz, 1H), 8.11 (dd, J = 5.3, 1.5 Hz, 1H), 8.42 (br, 1H), 8.57 (d, J =
1.6 Hz, 1H), 8.63 (dd, J = 4.9, 1.6 Hz, 1H), 8.84 (br, 1H). UPLC-MS
(short basic) tR 2.04 (560 [M + H]+).
N- ( 2 -B romobenzy l ) -N - ( 2 -oxo -2 - ( ( 2 ′ - o xo -1 , 1 ′ , 2 ′ , 3 -
tetrahydrospiro[indene-2,3′-pyrrolo[2,3-b]pyridin]-5-yl)amino)-
ethyl)pivalamide (21E). 21C (3.11 g, 9.48 mmol), EDCI.HCl (2.5 g,
13.27 mmol), and HOAt (1.8 g, 13.27 mmol) were dissolved in dry
DMF (60 mL). N,N-Diisopropylethylamine (5.0 mL, 28.44 mmol)
and 21D (2.38 g, 9.48 mmol) were added, and the mixture was stirred
at rt for 18 h. The mixture was diluted with ethyl acetate (250 mL)
and washed with saturated sodium bicarbonate and three times with
brine. The organic layer was dried over magnesium sulfate, filtered,
and the filtrate was evaporated. The residue was purified via flash
silica chromatography (0−100% EtOAc in DCM) to provide 21E
(4.38 g, 83%) as a pale yellow solid. 1H NMR (CDCl3, 300 MHz) δ
1.31 (s, 9H), 3.04 (dd, J = 15.7, 6.4 Hz, 2H), 3.61 (dd, J = 15.8, 6.0
Hz, 2H), 4.07 (s, 2H), 4.91 (s, 2H), 6.81 (dd, J = 7.2, 5.4 Hz, 1H),
7.07 (d, J = 7.1 Hz, 1H), 7.12−7.24 (m, 3H), 7.34 (t, J = 7.5 Hz, 1H),
7.55−7.62 (m, 2H), 8.12 (dd, J = 5.2 Hz, 1H), 8.49 (s, 1H), 9.29 (s,
1H). UPLC-MS (short basic) tR 0.84 (561, 563 [M + H]+).
N- ( 2 -Cyanobenzy l ) -N - ( 2 - o xo - 2 - ( ( 2 ′ - o xo - 1 , 1 ′ , 2 ′ , 3 -
tetrahydrospiro[indene-2,3′-pyrrolo[2,3-b]pyridin]-5-yl)amino)-
ethyl)pivalamide (21). 21E (4.40 g, 7.84 mmol) was dissolved in dry
DMF (88 mL) and was degassed by bubbling argon through the
solution. Zinc(II) cyanide (1.66 g, 14.12 mmol) and tetrakis-
(triphenylphosphine)palladium(0) (1.8 g, 1.57 mmol) were added,
and the mixture was stirred at 130 °C for 2 h. UPLC-MS indicated
complete conversion. The heat was removed, and the mixture was
stirred at rt for 18 h. The mixture was then diluted with ethyl acetate
(400 mL) and washed twice with saturated sodium bicarbonate and
three times with brine. The organic layer was dried over magnesium
sulfate, filtered, and the filtrate was evaporated. The residue was
triturated with diethyl ether to provide 21 (3.85 g, 96%) as an off-
white solid. 1H NMR (CD3OD, 300 MHz) δ 1.24 (s, 9H), 3.03 (dd, J
= 16.0, 10.7 Hz, 2H), 3.30 (dd, J = 16.0, 9.2 Hz, 2H), 4.04 (s, 2H),
5.02 (s, 2H), 6.82 (dd, J = 7.3, 5.3 Hz, 1H), 6.90 (d, J = 6.9 Hz, 1H),
7.10−7.55 (m, 7H), 8.00−8.05 (m, 2H), 9.75 (s, 1H), 10.94 (s, 1H).
N-(2-(Aminomethyl)benzyl)-N-(2-oxo-2-((2′-oxo-1,1′,2′,3-
tetrahydrospiro[indene-2,3′-pyrrolo[2,3-b]pyridin]-5-yl)amino)-
ethyl)pivalamide (12). 21 (2.3 g, 4.53 mmol) was dissolved in 15%
ammonia in methanol (180 mL) under an argon atmosphere in an
autoclave. Raney nickel (250 mg, 0.45 mmol) was added, and
hydrogen was introduced to 500 psi. The vessel was stirred at 60 °C
for 6 h and then at rt for 18 h. UPLC-MS showed 20% conversion, so
extra Raney nickel (400 mg, 0.72 mmol) was added and hydrogen was
reintroduced to 500 psi. The vessel was stirred at 60 °C for 6.5 h.
UPLC-MS analysis showed 58% conversion. The mixture was
decanted (from the nickel solids) and filtered through celite, washing
with 15% ammonia in methanol, and the filtrate was evaporated. The
residue was dissolved in 15% ammonia in methanol (180 mL) under
an argon atmosphere in an autoclave. Raney nickel (400 mg, 0.72
mmol) was added, and hydrogen was reintroduced to 500 psi. The
vessel was stirred at 50 °C for 6 h, then rt for 18 h, 55 °C for 6 h, rt
for 42 h, and 55 °C for 8 h. The mixture was decanted (from the
nickel solids) and filtered through celite, washing with 15% ammonia
in methanol, and the filtrate was evaporated. The residue was purified
via flash silica chromatography (EtOAc and then 5% MeOH in DCM,
then 10−15% MeOH with ammonia in DCM) to provide 12 (240
mg, 10%) as a white powder after freeze-drying from an aqueous
solution. 1H NMR (CD3OD, 300 MHz) δ 1.32 (s, 9H), 3.04 (dd, J =
15.9, 5.4 Hz, 2H), 3.49 (dd, J = 15.8, 9.8 Hz, 2H), 3.81 (s, 2H), 4.06
(br s, 2H), 4.93 (br s, 2H), 6.86 (dd, J = 7.3, 5.4 Hz, 1H), 7.09−7.41
(m, 7H), 7.53 (s, br, 1H), 8.03 (dd, J = 5.3, 1.5 Hz, 1H). UPLC-MS
(long basic) tR 1.79 (512 [M + H]+), 84% purecontains 6% mono-
N-methyl and 3% di-N-methylamine byproducts.
2-((N-(2-Oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-
pyrrolo[2,3-b]pyridin]-5-yl)amino)ethyl)pivalamido)methyl)-
benzamide (15). 21 (17 mg, 0.033 mmol) was dissolved in DMSO (1
mL). Water (0.17 mL) was added, followed by hydrogen peroxide
solution (3 drops) and NaOH (2.8 mg, 0.07 mmol), and the mixture
was stirred at rt for 2 h. The reaction mixture was quenched with ethyl
acetate and water. The aqueous layer was extracted with ethyl acetate
(repeated twice). The organics were washed with brine, dried over
magnesium sulfate, filtered, and the filtrate was evaporated. The
residue was purified twice via column chromatography (1:0 ethyl
acetate/methanol to 15:1 ethyl acetate/methanol) to provide 15
(10.6 mg, 60%) as a pale yellow solid. 1H NMR (CD3OD, 300 MHz)
δ 1.31 (s, 9H), 3.04 (dd, J = 15.8, 5.2 Hz, 2H), 3.48 (dd, J = 15.9, 7.5
Hz, 2H), 4.11 (s, 2H), 5.06 (s, 2H), 6.86 (dd, J = 7.3, 5.3 Hz, 1H),
7.11 (dd, J = 7.3, 1.6 Hz, 1H), 7.20 (d, J = 8.2 Hz, 2H), 7.30−7.39
(m, 3H), 7.44−7.55 (m, 3H), 8.03 (dd, J = 5.4, 1.6 Hz, 1H). UPLC-
MS (short basic) tR 1.65 (526 [M + H]+).
Methyl 2-((2-(2-(Diallylamino)ethyl)benzyl)amino)acetate (16B).
16A (116 mg, 0.516 mmol) was dissolved in methanol (2 mL), and
then methyl glycinate hydrochloride (191 mg, 1.52 mmol) and
sodium cyanoborohydride (55 mg, 0.88 mmol) were added and the
mixture was stirred at rt for 18 h. The reaction mixture was poured
into water, and the pH was adjusted to 4 with 2 M HCl before the
mixture was washed twice with dichloromethane. The aqueous layer
was basified with sodium carbonate and extracted twice with
dichloromethane. This organic extract was dried over magnesium
sulfate, filtered, and evaporated to provide 16B (53 mg, 35%) as a
colorless oil. 1H NMR (CDCl3, 300 MHz) δ 2.63−2.88 (m, 4H), 3.19
(d, J = 6.5 Hz, 4H), 3.44 (s, 2H), 3.73 (s, 3H), 3.79 (s, 2H), 5.11−
5.24 (m, 4H), 5.80−5.95 (m, 2H), 7.12−7.32 (m, 4H). UPLC-MS
(short basic) tR 0.84 (303 [M + H]+), 80% pure.
Methyl 2-(N-(2-(2-(Diallylamino)ethyl)benzyl)pivalamido)-
acetate. 16B (54 mg, 0.18 mmol) was dissolved in dichloromethane
(1 mL) under an argon atmosphere, and N,N-diisopropylethylamine
(93 μL, 0.53 mmol) was added. Trimethylacetyl chloride (26 μL, 0.21
mmol) was added dropwise, and the mixture was stirred at rt for 4
days. The mixture was poured into saturated sodium bicarbonate and
extracted three times with dichloromethane. The organic extracts
were evaporated to provide methyl 2-(N-(2-(2-(diallylamino)ethyl)-
benzyl)pivalamido)acetate (68 mg, 99%) as a colorless oil. UPLC-MS
(short basic) tR 0.96 (387 [M + H]+), 89% pure.
2-(N-(2-(2-(Diallylamino)ethyl)benzyl)pivalamido)acetic Acid
(16C). Methyl 2-(N-(2-(2-(diallylamino)ethyl)benzyl)pivalamido)-
acetate (68 mg, 0.176 mmol) was dissolved in methanol (1 mL),
and then 2.5 M sodium hydroxide (0.22 mL, 0.55 mmol) was added
and the mixture was stirred at rt for 18 h. The volatiles were removed,
the material was diluted with water, and the pH was adjusted to 5
with 2 M HCl. This was then concentrated to dryness to provide 16C
(assume 0.176 mmol) as a glass that was used directly in the next step.
N-(2-(2-(Diallylamino)ethyl)benzyl)-N-(2-oxo-2-((2′-oxo-
1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-b]pyridin]-5-yl)-
amino)ethyl)pivalamide (16E). 16C (∼0.176 mmol), EDCI.HCl (53
mg, 0.28 mmol), and HOAt (38 mg, 0.28 mmol) were dissolved in
dry DMF (1 mL). N,N-Diisopropylethylamine (0.11 mL, 0.64 mmol)
and 16D (44.5 mg, 0.177 mmol) were added, and the mixture was
stirred at rt for 18 h. The mixture was poured into saturated sodium
bicarbonate and extracted three times with ethyl acetate. The
combined organic layers were washed with brine, dried over
magnesium sulfate, filtered, and the filtrate was evaporated. The
residue was purified via flash silica chromatography (EtOAc) to
provide 16E (77 mg, 72%) as a pale yellow glass. 1H NMR (CDCl3,
400 MHz) δ 1.32 (s, 9H), 2.61−2.79 (m, 4H), 3.03 (dd, J = 15.8, 8.8
Hz, 2H), 3.17 (d, J = 6.1 Hz, 4H), 3.61 (dd, J = 15.5, 8.3 Hz, 2H),
4.02 (br s, 2H), 4.90 (s, 2H), 5.07−5.23 (m, 4H), 5.78−5.90 (m,
2H), 6.80 (dd, J = 7.3, 5.4 Hz, 1H), 7.03−7.27 (m, 7H), 7.56 (s, 1H),
8.15 (br s, 1H), 8.45 (s, 1H). UPLC-MS (long basic) tR 2.65 (606
[M + H]+), 98% pure.
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ethyl)pivalamide (16). 16E (77 mg, 0.127 mmol) and N,N′-
dimethylbarbituric acid (125 mg, 0.801 mmol) were dissolved in
dry degassed dichloromethane (2 mL) and degassed again. Tetrakis-
(triphenylphosphine)palladium(0) (11.4 mg, 0.010 mmol) was
added, and the mixture was stirred at 35 °C for 2 h and at rt for
18 h. UPLC-MS analysis showed incomplete reaction. Tetrakis-
(triphenylphosphine)palladium(0) (13 mg, 0.011 mmol) was added,
and the mixture was stirred at 35 °C for 3.5 h. UPLC-MS still showed
incomplete conversion. The mixture was diluted with dichloro-
methane and saturated sodium bicarbonate, and layers were
separated. The aqueous layer was extracted with dichloromethane.
The combined organic layers were dried over magnesium sulfate,
filtered, and the filtrate was evaporated. The aqueous layer was back-
extracted twice with ethyl acetate, the combined organic layers were
dried over magnesium sulfate, filtered, and the filtrate was evaporated.
The extracted residues were combined and shown to contain
monoallyl byproduct. The product was still in the aqueous layer,
which was evaporated and purified using a Biotage Isolera (18 g, C18
Ultra cartridge, 60−80% acetonitrile/water with pH 10 buffer) to
provide crude 16. This was further purified via MDAP (XBridge C18
19 × 150, 35−50% acetonitrile water with 0.1% ammonium
hydroxide) to provide 16 (19.4 mg, 29%) as a pale yellow glass. 1H
NMR (CDCl3, 300 MHz) δ 1.33 (s, 9H), 2.78 (t, J = 6.9 Hz, 2H),
2.93−3.07 (m, 4H), 3.59 (d, J = 15.5 Hz, 2H), 4.05 (br s, 2H), 4.97
(br s, 2H), 6.80 (dd, J = 7.3, 5.3 Hz, 1H), 7.03−7.26 (m, 8H), 7.53 (s,
1H), 8.11 (dd, J = 5.3, 1.4 Hz, 1H), 8.62 (s, 1H). UPLC-MS (long
basic) tR 1.79 (526 [M + H]+), 94% pure.
tert-Butyl 8-(((2-Methoxy-2-oxoethyl)amino)methyl)-3,4-dihy-
droisoquinoline-2(1H)-carboxylate (17B). 17A (80 mg, 0.306
mmol) was dissolved in dichloromethane (5 mL), and N,N-
diisopropylethylamine (0.20 mL, 1.22 mmol) and glycine methyl
ester hydrochloride (115 mg, 0.918 mmol) were added, followed by
magnesium sulfate. The mixture was stirred at rt for 4 h. Sodium
triacetoxyborohydride (97 mg, 0.46 mmol) was added, and stirring
was continued at rt for 72 h. The reaction mixture was poured into
saturated sodium bicarbonate and extracted with dichloromethane.
The organic extract was dried over sodium sulfate, filtered, and
evaporated. UPLC-MS indicated a 1:1 mixture of imine and amine.
Repeating conditions with sodium triacetoxyborohydride in dichloro-
methane did not improve the ratio. The residue was dissolved in
methanol (10 mL), cooled on ice/water, and sodium borohydride (7
mg, 0.18 mmol) was added, and the mixture was stirred at rt for 1.5 h.
The mixture was diluted with ethyl acetate and washed with saturated
sodium bicarbonate. The aqueous layer was extracted with ethyl
acetate, and the organic extracts were washed with water, dried over
sodium sulfate, filtered, and evaporated to provide 17B (150 mg,
quantitative yield) as a yellow oil that was used directly in the next
step. UPLC-MS (short basic) tR 0.83 (335 [M + H]+).
tert-Butyl 8-((N-(2-Methoxy-2-oxoethyl)pivalamido)methyl)-3,4-
dihydroisoquinoline-2(1H)-carboxylate. 17B (148 mg, ∼0.407
mmol) was dissolved in dichloromethane (3 mL) under an argon
atmosphere, and N,N-diisopropylethylamine (140 μL, 0.80 mmol)
was added. Trimethylacetyl chloride (50 μL, 0.40 mmol) was added
dropwise, and the mixture was stirred at rt for 3 h after which time
UPLC-MS indicated that amine had been completely consumed. The
mixture was poured into saturated sodium bicarbonate and extracted
three times with dichloromethane. The organic extracts were dried
over sodium sulfate, filtered, and the filtrate was evaporated. The
residue was purified via flash silica SPE (5 g SiO2 SPE, 15% EtOAc in
DCM) to provide tert-butyl 8-((N-(2-methoxy-2-oxoethyl)-
pivalamido)methyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (35
mg, 20%) as a colorless gum. UPLC-MS (short basic) tR 0.93 (419
[M + H]+), 80% pure.
2-(N-((2-(tert-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinolin-8-
yl)methyl)pivalamido)-acetic Acid (17C). tert-Butyl 8-((N-(2-me-
thoxy-2-oxoethyl)pivalamido)methyl)-3,4-dihydroisoquinoline-
2(1H)-carboxylate (35 mg, 0.084 mmol) was dissolved in methanol
(3 mL), and 2.5 M sodium hydroxide (50 μL, 0.125 mmol) was
added and the mixture was stirred at rt for 18 h. UPLC-MS indicated
incomplete hydrolysis, so a further 2.5 M sodium hydroxide (50 μL,
0.125 mmol) was added, and the mixture was stirred at rt for 72 h.
The reaction was diluted with ethyl acetate and washed with saturated
ammonium chloride. The aqueous layer was extracted twice with ethyl
acetate. The organic extracts were dried over sodium sulfate, filtered,
and the filtrate was evaporated to provide 17C (∼0.084 mmol) as a
glass, which was used directly in the next step. UPLC-MS (short
basic) tR 0.59 (405 [M + H]+).
tert-Butyl 8-((N-(2-Oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro-
[indene-2,3′-pyrrolo[2,3-b]pyridin]-5-yl)amino)ethyl)pivalamido)-
methyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (17E). 17C (35
mg, 0.084 mmol), EDCI.HCl (19 mg, 0.101 mmol), and HOAt (14
mg, 0.101 mmol) were dissolved in dry DMF (2 mL). N,N-
Diisopropylethylamine (35 μL, 0.20 mmol) and 17D (21 mg, 0.084
mmol) were added, and the mixture was stirred at rt for 18 h. The
mixture was poured into saturated sodium bicarbonate, and the
aqueous layer was extracted three times with ethyl acetate. The
organic extract was washed three times with water, dried over sodium
sulfate, filtered, and the filtrate was evaporated. The residue was
purified via SPE (2 g SiO2 EtOAc) to provide 17E (30 mg, 56%) as a
colorless glass. UPLC-MS (short basic) tR 0.86 (638 [M + H]+).
N-(2-Oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-
pyrrolo[2,3-b]pyridin]-5-yl)amino)ethyl)-N-((1,2,3,4-tetrahydroiso-
quinolin-8-yl)methyl)pivalamide (17). 17E (30 mg, 0.047 mmol)
was dissolved in dichloromethane (3 mL). Trifluoroacetic acid (0.3
mL) was added, and the solution was stirred at rt for 45 min. The
mixture was poured into saturated sodium bicarbonate, and the
aqueous layer was extracted three times with dichloromethane. The
organic extract was dried over sodium sulfate, filtered, and the filtrate
was evaporated. The residue was purified via SPE (2 g SiO2 10%
MeOH in EtOAc and then 10−20% MeOH in DCM) to provide 17
(12 mg, 48%) as a colorless glass. 1H NMR (CD3OD, 300 MHz) δ
1.31 (s, 9H), 2.88 (t, J = 5.9 Hz, 2H), 3.01−3.12 (m, 4H), 3.49 (dd, J
= 15.8, 7.6 Hz, 2H), 3.94 (s, 2H), 4.10 (br s, 2H), 4.74 (br s, 2H),
6.86 (dd, J = 7.3, 5.4 Hz, 1H), 6.99 (d, J = 7.0 Hz, 1H), 7.04−7.23
(m, 4H), 7.34 (dd, J = 8.2, 1.5 Hz, 1H), 7.52 (s, 1H), 8.03 (dd, J =
5.3, 1.6 Hz, 1H). UPLC-MS (short basic) tR 0.66 (538 [M + H]+),
99% pure.
Ethyl 2-((2-((tert-Butoxycarbonyl)amino)benzyl)amino)acetate
(11B). 11A (100 mg, 0.45 mmol), ethyl bromoacetate (38 μL, 0.34
mmol), and N,N-diisopropylethylamine (157 μL, 0.90 mmol) were
mixed in DMF (1 mL) and stirred at rt for 2 h, after which the
reaction was complete by UPLC-MS. The mixture was diluted with
ethyl acetate and washed with water. The aqueous layer was extracted
with ethyl acetate. The organics were washed with brine, dried over
magnesium sulfate, filtered, and the filtrate was evaporated to provide
11B (119 mg, 86%) as a yellow gum. 1H NMR (CDCl3, 300 MHz) δ
1.26 (t, J = 4.6 Hz, 3H), 1.52 (s, 9H), 3.36 (s, 2H), 3.84 (s, 2H), 4.21
(q, J = 7.2 Hz, 2H), 6.93 (dt, J = 5.8, 1.4 Hz, 1H), 7.06 (dd, J = 7.7,
1.6 Hz, 1H), 7.23−7.31 (m, 1H), 7.98 (br d, 1H), 9.14 (br s, 1H).
Ethyl 2-(N-(2-((tert-Butoxycarbonyl)amino)benzyl)pivalamido)-
acetate. 11B (119 mg, 0.39 mmol) was dissolved in dichloromethane
(5 mL), and N,N-diisopropylethylamine (204 μL, 1.17 mmol) and
trimethylacetyl chloride (58 μL, 0.47 mmol) were added and the
mixture was stirred at rt for 2 h. UPLC-MS showed little reaction, so
further N,N-diisopropylethylamine (204 μL, 1.17 mmol) and
trimethylacetyl chloride (58 μL, 0.47 mmol) were added. After an
additional 2 h, UPLC-MS showed complete reaction. The mixture
was poured into water, and the aqueous layer was extracted with
dichloromethane. The organics were dried over magnesium sulfate,
filtered, and evaporated. The residue was purified via flash
chromatography (4:1 heptane/ethyl acetate) to provide the
intermediate of 11C (99 mg, 65%) as a colorless oil. 1H NMR
(CDCl3, 300 MHz) δ 1.25 (t, J = 7.1 Hz, 3H), 1.30 (s, 9H), 1.51 (s,
9H), 4.00 (s, 2H), 4.18 (q, J = 7.1 Hz, 2H), 4.72 (s, 2H), 6.96−7.10
(m, 2H), 7.26−7.33 (m, 1H), 7.99 (br s, 1H). UPLC-MS (short CSH
2−50%) tR 1.50 (415 [M + Na]+), 95% pure.
2-(N-(2-((tert-Butoxycarbonyl)amino)benzyl)pivalamido)acetic
Acid 11C. An intermediate of 7C (99 mg, 0.25 mmol) was dissolved
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in methanol (1.5 mL), and 2.5 M sodium hydroxide (0.25 mL, 0.625
mmol) was added and the mixture was heated at reflux for 2 h. The
mixture was poured into water, and the pH was adjusted carefully to 4
by the addition of 2 M HCl, and the mixture was extracted with ethyl
acetate. The aqueous pH was again adjusted to 4, and the mixture was
extracted with ethyl acetate. The organics were washed with brine,
dried over magnesium sulfate, filtered, and the filtrate was evaporated
to provide 11C (80 mg, 88%) as a colorless solid. 1H NMR (CDCl3,
300 MHz) δ 1.31 (s, 9H), 1.50 (s, 9H), 4.03 (s, 2H), 4.75 (s, 2H),
7.05−7.14 (m, 2H), 7.26−7.34 (m, 2H), 7.82 (br s, 1H). UPLC-MS
(short CSH 2−50%) tR 1.28 (363 [M + Na]+), 95% pure.
tert-Butyl (2-((N-(2-Oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro-
[indene-2,3′-pyrrolo[2,3-b]pyridin]-5-yl)amino)ethyl)pivalamido)-
methyl)phenyl)carbamate (11E). 11C (80 mg, 0.22 mmol),
EDCI.HCl (50 mg, 0.26 mmol), and HOAt (35 mg, 0.26 mmol)
were dissolved in dry DMF (4 mL). N,N-Diisopropylethylamine (115
μL, 0.66 mmol) and 11D (55 mg, 0.22 mmol) were added, and the
mixture was stirred at rt for 4 h. The mixture was diluted with ethyl
acetate and washed with saturated sodium bicarbonate. The aqueous
layer was extracted twice with ethyl acetate. The combined organics
were washed with brine, dried over magnesium sulfate, filtered, and
the filtrate was evaporated. The residue was purified via flash silica
chromatography (1:1 heptane/acetone) to provide 11E (110 mg,
84%) as a colorless solid. 1H NMR (CDCl3, 300 MHz) δ 1.36 (s,
9H), 1.51 (s, 9H), 3.03 (dd, J = 15.8, 2.3 Hz, 2H), 3.60 (dd, J = 16.0,
3.6 Hz, 2H), 4.06 (br s, 2H), 4.83 (s, 2H), 6.81 (dd, J = 7.4, 5.3 Hz,
1H), 7.04−7.21 (m, 5H), 7.26−7.34 (m, 1H), 7.51 (s, 1H), 7.75 (br,
s, 1H), 8.12 (dd, J = 5.3, 1.6 Hz, 2H). UPLC-MS (short CSH 2−
50%) tR 1.31 (498 [M-Boc + H]+), 88% pure.
N- ( 2 -Am inobenzy l ) -N - ( 2 -o xo - 2 - ( ( 2 ′ - o xo -1 , 1 ′ , 2 ′ , 3 -
tetrahydrospiro[indene-2,3′-pyrrolo[2,3-b]pyridin]-5-yl)amino)-
ethyl)pivalamide (11). 11E (20 mg, 0.033 mmol) was dissolved in
dichloromethane (1 mL). Trifluoroacetic acid (0.05 mL) was added,
and the solution was stirred at rt for 7 h. The mixture was poured into
water, and the aqueous layer was extracted three times with
dichloromethane. The organic extract was dried over magnesium
sulfate, filtered, and the filtrate was evaporated. The residue was
purified via prep-HPLC (HP C18, ID 22 mm, length 150 mm, flow
rate 16 mL/min: 5−50% MeCN/water/0.1% trifluoroacetyl (TFA)
over 20 min) to provide 11 (10.3 mg, 48%) as a colorless glass (TFA
salt). 1H NMR (CD3OD, 400 MHz) δ 1.34 (s, 9H), 3.09 (dd, J =
15.8, 6.6 Hz, 2H), 3.53 (dd, J = 15.8, 2.8 Hz, 2H), 4.17 (br s, 2H),
4.61 (br s, 1H), 4.75 (br s, 2H), 6.72 (t, J = 7.3 Hz, 1H), 6.77 (d, J =
7.9 Hz, 1H), 6.91 (dd, J = 7.4, 5.4 Hz, 1H), 7.00 (d, J = 7.5 Hz, 1H),
7.06−7.11 (m, 1H), 7.16 (dd, J = 7.4, 1.5 Hz, 1H), 7.25 (d, J = 8.2
Hz, 1H), 7.39 (dd, J = 8.1, 1.6 Hz, 1H), 7.57 (br s, 1H), 8.07 (dd, J =




ethyl)pivalamide (24). 12 (15 mg, 0.03 mmol) and 4-benzyl-3,5-
dimethyl-1H-pyrazole-1-carboximidamide hydrochloride (prepared
according to the literature;47 30 mg, 0.117 mmol) and triethylamine
(15 mg, 0.15 mmol) were added to tetrahydrofuran (0.3 mL) and
acetonitrile (0.3 mL), and the mixture was heated at 90 °C under
microwave irradiation for 1 h. The mixture was diluted with methanol
and purified directly by prep-HPLC (HP C18, ID 22 mm, length 150
mm, flow 16 mL/min: 5−45% MeCN water/acetonitrile 0.1% TFA
over 20 min) to provide the desired 24 (8.9 mg, 55%) as a colorless
glass (TFA salt). 1H NMR (CD3OD, 400 MHz) δ 1.36 (s, 9H), 3.11
(dd, J = 15.9, 2.8 Hz, 2H), 3.53 (dd, J = 15.9, 8.9 Hz, 2H), 4.29 (br s,
2H), 4.45−4.50 (m, 2H), 4.85 (br s, 2H), 6.93 (dd, J = 7.3, 5.4 Hz,
1H), 7.19 (dd, J = 7.4, 1.5 Hz, 1H), 7.24 (d, J = 8.2 Hz, 1H), 7.28−
7.42 (m, 5H), 7.52 (br s, 1H), 7.80−7.85 (m, 1H), 8.08 (dd, J = 5.4,
1.5 Hz, 1H). HPLC: 98% pure. MS: 554 [M + H]+.
2-(1,1-Dimethoxyethyl)benzaldehyde (29E). 29A (830 mg, 3.39
mmol) was dissolved in dry tetrahydrofuran (10 mL) under an argon
atmosphere and cooled on dry ice/acetone. To this was added a
solution of n-butyllithium (2.04 mL, 5.09 mmol, 2.5 M in hexanes)
dropwise so that the internal temperature stayed below −60 °C (10
min addition). The reaction was stirred on dry ice/acetone for 60
min. To this was added DMF (0.525 mL, 6.78 mmol) in one portion.
The mixture was stirred on dry ice/acetone for 60 min before being
allowed to warm to rt over 18 h. Water was added, and the mixture
was extracted three times with ethyl acetate. The combined organic
extracts were washed with brine, dried over magnesium sulfate,
filtered, and the filtrate was evaporated to provide 29E (634 mg, 96%)
as a straw-colored oil. 1H NMR (CDCl3, 300 MHz) δ 1.70 (s, 3H),
3.23 (s, 6H), 7.36−7.44 (m, 1H), 7.50−7.57 (m, 1H), 7.64 (dd, J =
7.9, 1.3 Hz, 1H), 7.86 (dd, J = 7.7, 1.4 Hz, 1H), 10.64 (s, 1H).
Methyl 2-((2-(1,1-Dimethoxyethyl)benzyl)amino)acetate (29B).
29E (634 mg, 3.26 mmol) was dissolved in dichloromethane (25 mL)
under an argon atmosphere. N,N-Diisopropylethylamine (1.14 mL,
6.52 mmol) was added followed by methyl glycinate hydrochloride
(777 mg, 6.19 mmol) and magnesium sulfate (excess). The mixture
was stirred at rt for 1 h. Sodium triacetoxyborohydride (1.1 g, 5.2
mmol) was added, and the mixture was stirred at rt for 18 h. The
mixture was poured into water, and the aqueous layer was extracted
three times with dichloromethane. The combined organic extracts
were washed with brine, dried over magnesium sulfate, filtered, and
the filtrate was evaporated to provide 29B (717 g, 82%) as a pale
straw-colored gum. 1H NMR (CDCl3, 300 MHz) δ 1.58 (s, 3H), 3.23
(s, 6H), 3.50 (s, 2H), 3.72 (s, 3H), 3.98 (s, 2H), 7.26−7.30 (m, 2H),
7.37−7.42 (m, 1H), 7.52−7.57 (m, 1H).
Methyl 2-(N-(2-(1,1-Dimethoxyethyl)benzyl)pivalamido)acetate.
29B (685 mg, 2.56 mmol) was dissolved in dichloromethane (40 mL)
under an argon atmosphere, and N,N-diisopropylethylamine (1.34
mL, 7.68 mmol) was added. Trimethylacetyl chloride (0.38 mL, 3.07
mmol) was added dropwise. The mixture was stirred at rt for 3 h after
which the reaction had reached completion, as judged by TLC
analysis. The mixture was poured into water, and the aqueous layer
was extracted three times with dichloromethane. The combined
organic extracts were washed with brine, dried over magnesium
sulfate, filtered, and the filtrate was evaporated to provide methyl 2-
(N-(2-(1-aminoethyl)benzyl)pivalamido)acetate (1.012 g, quantita-
tive yield) as a yellow gum. 1H NMR (CDCl3, 300 MHz) δ 1.32 (s,
9H), 1.52 (s, 3H), 3.20 (s, 6H), 3.72 (s, 3H), 5.02 (br s, 2H), 7.25−




(500 mg, 1.40 mmol) was dissolved in methanol (5 mL), and 2.5
M sodium hydroxide (0.84 mL, 2.1 mmol) was added. The mixture
was stirred at rt for 3 h, after which the reaction had reached
completion, as judged by TLC analysis. The mixture was diluted with
water, and the pH was adjusted very carefully to pH 4 with 10%
potassium hydrogen sulfate. Once at pH 4, the aqueous layer was
extracted twice with ethyl acetate. The combined organic extracts
were washed with brine, dried over magnesium sulfate, filtered, and
evaporated carefully (30 °C water bath, not to dryness). 29C was
used directly in the next step as the compound is not stable.
N-(2-(1,1-Dimethoxyethyl)benzyl)-N-(2-oxo-2-((2′-oxo-1,1′,2′,3-
tetrahydrospiro[indene-2,3′-pyrrolo[2,3-b]pyridin]-5-yl)amino)-
ethyl)pivalamide (29F). 29C (∼1.40 mmol) was dissolved in DMF
(15 mL) under an argon atmosphere, and N,N-diisopropylethylamine
(0.73 mL, 4.2 mmol) was added. EDCI.HCl (322 mg, 1.68 mmol)
and HOAt (229 mg, 1.68 mmol) were added, followed by 29D (387
mg, 1.54 mmol). The mixture was stirred at rt for 3 days. The mixture
was poured into saturated sodium bicarbonate. The aqueous layer was
extracted three times with ethyl acetate. The combined organic
extracts were washed three times with water, dried over sodium
sulfate, filtered, and the filtrate was evaporated. The residue was
purified via column chromatography (300 mL silica, 2:1 heptane/
acetone) to provide 29F (247 mg, 31%) as a colorless glass. 1H NMR
(CDCl3, 300 MHz) δ 1.34 (s, 9H), 1.59 (s, 3H), 2.94−3.08 (m, 2H),
3.22 (s, 6H), 3.53−3.67 (m, 4H), 5.10 (br s, 2H), 6.58−6.63 (m,
1H), 6.75−6.84 (m, 1H), 7.02−7.07 (m, 2H), 7.15−7.23 (m, 1H),
7.26−7.37 (m, 3H), 8.05 (br s, 1H), 8.07−8.12 (m, 1H), 8.62 (br s,
1H).
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(29G). 29F (247 mg, 0.43 mmol) was dissolved in acetone (15 mL),
and p-toluene sulfonic acid monohydrate (89 mg, 0.47 mmol) was
added. The mixture was stirred at rt for 4 h, at which point further p-
toluene sulfonic acid monohydrate (33 mg, 0.17 mmol) was added
and the reaction was stirred for a further 1 h. The mixture was poured
into saturated sodium bicarbonate. The aqueous layer was extracted
three times with ethyl acetate. The combined organic extracts were
washed with brine, dried over sodium sulfate, filtered, and the filtrate
was evaporated to provide 29G (89 mg, 39%) as a colorless solid. 1H
NMR (CDCl3, 300 MHz) δ 1.31 (s, 9H), 2.64 (s, 3H), 3.04 (dd, J =
15.8, 7.4, 2H), 3.62 (dd, J = 15.7, 6.2 Hz, 2H), 4.05 (s, 2H), 5.23 (s,
2H), 6.82 (dd, J = 7.3, 5.3 Hz, 1H), 7.07 (dd, J = 7.3, 1.6 Hz, 1H),
7.16−7.31 (m, 3H), 7.42 (t, J = 7.2 Hz, 1H), 7.52−7.56 (m, 2H),
7.89 (d, J = 7.5 Hz, 1H), 8.11 (dd, J = 5.3, 1.5 Hz, 1H), 8.63 (br s,
1H). UPLC-MS tR 0.75 (524 [M + H]+), 90% pure.
N-(2-(1-Aminoethyl)benzyl)-N-(2-oxo-2-((2′-oxo-1,1′,2′,3-
tetrahydrospiro[indene-2,3′-pyrrolo[2,3-b]pyridin]-5-yl)amino)-
ethyl)pivalamide (29). 29G (83 mg, 0.17 mmol) was dissolved in
methanol (3.5 mL), and ammonium acetate (131 mg, 1.7 mmol) and
sodium cyanoborohydride (21 mg, 0.34 mmol) were added. The
mixture was stirred at reflux for 18 h. Extra ammonium acetate (131
mg, 1.7 mmol) and sodium cyanoborohydride (21 mg, 0.34 mmol)
were added, and the mixture was stirred at 50 °C for 72 h. The
mixture was poured into water, and the aqueous layer was extracted
with dichloromethane. The organic extract was evaporated, and the
residue was purified via prep-HPLC (XBridge C18, ID 19 mm, length
150 mm, flow rate 20 mL/min: 40−60% MeCN in pH 10
[NH4HCO3 with NH4OH] over 8 min) to provide 29 (15 mg,
17%) as a colorless solid. 1H NMR (CD3OD, 300 MHz) δ 1.29−1.37
(m, 12H), 3.05 (dd, J = 15.6, 6.1 Hz, 2H), 3.49 (dd, J = 15.5, 10.6 Hz,
2H), 3.38−4.37 (m, 2H), 4.86−5.00 (m, 2H), 6.84−6.89 (m, 1H),
7.09−7.16 (m, 2H), 7.18−7.27 (m, 2H), 7.29−7.35 (m, 2H), 7.49−
7.56 (m, 2H), 8.01−8.05 (m, 1H). UPLC-MS (long run) tR 1.86
(526 [M + H]+), 99% pure (Scheme 5).
Methyl 2-((1-(2-Bromophenyl)ethyl)amino)acetate (28B). 28A (5
g, 25 mmol) was dissolved in methanol (9.8 mL), and then methyl
glycinate hydrochloride (15.69 g, 125 mmol) and sodium
cyanoborohydride (3.14 g, 62.84 mmol) were added and the mixture
was stirred at rt over the weekend. The reaction mixture was poured
into water, and the pH was adjusted to 4 with 2 M HCl before the
mixture was washed twice with dichloromethane. The aqueous layer
was basified with sodium carbonate and extracted twice with
dichloromethane. This organic extract was dried over magnesium
sulfate, filtered, and evaporated. The residue was purified by Isolera
(acetonitrile/NH4COOH buffer pH =10) to provide 28B (1.857 g,
27%). UPLC-MS (short basic) tR 0.88 (273 [M + H]+).
Methyl 2-(N-(1-(2-Bromophenyl)ethyl)pivalamido)acetate 28C.
28B (1.86 g, 6.8 mmol) was dissolved in dichloromethane (50 mL)
under an argon atmosphere, and N,N-diisopropylethylamine (3.55
mL, 20.4 mmol) was added and the mixture was stirred at 5 °C (ice/
water). Trimethylacetyl chloride (1 mL, 8.16 mmol) was added
dropwise, and the mixture was stirred at rt for 4 h. The reaction
mixture was diluted in dichloromethane, washed with brine and
saturated sodium bicarbonate, dried over magnesium sulfate, filtered,
and the filtrate was evaporated. The residue was purified by flash
chromatography eluting with heptane/acetone = 4:1 to provide the
intermediate of 28C (2.2 g, 91%). UPLC-MS (short basic) tR 0.98
(357 [M + H]+).
Methyl 2-(N-(1-(2-Cyanophenyl)ethyl)pivalamido)acetate. 28C
(100 mg, 0.28 mmol) was dissolved in dry DMF (3 mL) and was
degassed by bubbling argon through the solution. Zinc(II) cyanide
(59 mg, 0.5 mmol) and tetrakis(triphenylphosphine)palladium(0)
(65 mg, 0.056 mmol) were added, and the mixture was stirred at 130
°C for 1 h. The mixture was diluted with ethyl acetate and washed
twice with saturated sodium bicarbonate and three times with brine.
The organic layer was dried over magnesium sulfate, filtered, and the
filtrate was evaporated. The crude was directly purified using a
Biotage Isolera (C18 Ultra cartridge, 0−20% acetone/heptane) to
provide the intermediate of 28D (67 mg, 79%). 1H NMR (CDCl3,
300 MHz) δ 1.24 (s, 9H), 1.68 (s, 3H), 3.74 (s, 3H), 4.52 (d, J = 17.3
Hz, 1H), 7.31−7.45 (m, 2H), 7.58 (t, J = 7.6 Hz, 1H), 7.67 (d, J = 7.9
Hz, 1H). UPLC-MS (short basic) tR 0.79 (303.2 [M + H]+).
Methyl 2-(N-(1-(2-(Aminomethyl)phenyl)ethyl)pivalamido)-
acetate (28D). An intermediate of 28D (67 mg, 0.22 mmol) was
dissolved in a mixture of methanol (4.5 mL) and TFA (0.5 mL).
Palladium-on-carbon (10% wet, 30 mg) was added, the vessel was
sealed, and an atmosphere of hydrogen was introduced using a
balloon. The mixture was stirred at rt for 5 h. The reaction was filtered
through celite, washed with methanol, and the filtrate was evaporated
to provide 28D. UPLC-MS (long basic) tR 0.68 (307 [M + H]+),
84% pure.
Methyl 2-(N-(1-(2-((((Benzyloxy)carbonyl)amino)methyl)phenyl)-
ethyl)pivalamido)acetate. 28D (67 mg, 0.22 mmol) in dichloro-
methane (2 mL) and triethylamine (92 μL, 0.66 mmol) was added to
benzyl chloroformate (34 μL, 0.24 mmol). The mixture was stirred at
rt for 4 h, quenched by adding water, and extracted with
dichloromethane. The combined organic phases were dried over
sodium sulfate. After filtration and concentration, the residue was
purified by silica gel column chromatography, eluting with heptane/
acetone = 4:1 to provide the intermediate of 28E (62 mg, 64% yield).
1H NMR (CDCl3, 300 MHz) δ 1.21 (s, 9H), 1.42 (d, J = 6.5 Hz, 3H),
3.34 (s, 3H), 4.01 (d, J = 18.0 Hz, 1H), 4.20 (d, J = 18.0 Hz), 4.39 (d,
J = 5.5 Hz, 2H), 5.12 (s, 2H), 5.95 (s, 1H), 6.18 (s, 1H), 7.23−7.38
(m, 9H). UPLC-MS (short basic) tR 0.89 (441 [M + H]+).
2-(N-(1-(2-((((Benzyloxy)carbonyl)amino)methyl)phenyl)ethyl)-
pivalamido)acetic Acid (28E). An intermediate of 28E (62 mg, 0.14
mmol) was dissolved in methanol (1 mL), and 2.5 M sodium
hydroxide (168 μL, 0.42 mmol) was added and the mixture was
Scheme 5. Synthesis of 28
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stirred at rt over the weekend. The volatiles were removed, and the
residue was dissolved in water. The pH was adjusted carefully to 4 by
the addition of 2 M HCl, and the mixture was extracted with ethyl
acetate. The aqueous pH was again adjusted to 4, and the mixture was
extracted with ethyl acetate. The organics were washed with brine,
dried over magnesium sulfate, filtered, and the filtrate was evaporated
to provide 28E (68 mg, quantitative yield) that was used directly in
the next step. UPLC-MS (short basic) tR 0.51 (427 [M + H]+).
Benzyl 2-(1-(N-(2-Oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro-
[indene-2,3′-pyrrolo[2,3-b]pyridin]-5-yl)amino)ethyl)pivalamido)-
ethyl)benzylcarbamate. 28E (60 mg, 0.14 mmol) was dissolved in
DMF (1.5 mL) under an argon atmosphere, and N,N-diisopropyle-
thylamine (73 μL, 0.42 mmol) was added. EDCI·HCl (33 mg, 0.17
mmol) and HOAt (23 mg, 0.17 mmol) were added followed by 28F
(38 mg, 0.15 mmol). The mixture was stirred at rt overnight. The
reaction mixture was poured into saturated sodium bicarbonate and
extracted three times with ethyl acetate and brine, dried over
magnesium sulfate, filtered, and the filtrate was evaporated. The
residue was purified by column chromatography (4:1 heptane/
acetone) to provide benzyl 2-(1-(N-(2-oxo-2-((2′-oxo-1,1′,2′,3-
tetrahydrospiro[indene-2,3′-pyrrolo[2,3-b]pyridin]-5-yl)amino)-
ethyl)pivalamido)ethyl)benzylcarbamate (90 mg, 97%). UPLC-MS
(short basic) tR 0.80 (658 [M + H]+).
N-(1-(2-(Aminomethyl)phenyl)ethyl)-N-(2-oxo-2-((2′-oxo-
1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-b]pyridin]-5-yl)-
amino)ethyl)pivalamide. To a solution of benzyl 2-(1-(N-(2-oxo-2-
((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-b]pyridin]-
5-yl)amino)ethyl)pivalamido)ethyl)benzylcarbamate (90 mg, 0.14
mmol) in ethanol (2 mL) was added 10% Pd/C (9 mg) under a
nitrogen atmosphere. The suspension was degassed under vacuum
and purged with hydrogen three times. The resulting mixture was
stirred under 700 psi of hydrogen pressure at 50 °C for 9 h. The
mixture was filtered through celite, and the filter liquid was
concentrated and purified by preparative HPLC (acetonitrile/
NH4COOH buffer over 8 min) to provide 28 (33 mg, 45% yield).
1H NMR (CDCl3, 300 MHz) δ 1.28 (s, 9H), 1.49 (d, J = 6.7 Hz, 3H),
3.03 (s, 2H), 3.47 (dd, J = 15.5, 4.0 Hz, 2H), 3.82 (d, J = 14.1 Hz,
1H), 3.99 (d, J = 14.1 Hz, 1H), 4.28 (s, 1H), 6.10 (s, 1H), 6.83−6.91
(m, 1H), 7.03−7.48 (m, 8H), 8.02−8.05 (m, 1H). UPLC-MS (short
basic) tR 1.80 (526 [M + H]+)(Scheme 6).
N-(2-((((1H-Imidazol-2-yl)methyl)amino)methyl)benzyl)-N-(2-
oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-b]-
pyridine]-5-yl)amino)ethyl)pivalamide (23). 23A (30 mg, 0.059
mmol) was dissolved in dichloromethane (3 mL), and 23B (12 mg,
0.076 mmol) was added. N,N-Diisopropylethylamine (0.028 mL, 0.15
mmol) and magnesium sulfate were added, and the mixture was
stirred at rt. After 20 h, sodium triacetoxyborohydride (20 mg, 0.094
mmol) was added, and the reaction was stirred at room temperature,
monitoring by UPLC-MS. Extra sodium triacetoxyborohydride (20
mg, 0.094 mmol) was added as required. Once complete, the reaction
was poured into saturated sodium bicarbonate and the mixture was
extracted three times with dichloromethane. The combined organics
were dried over sodium sulfate, filtered, and evaporated. The crude
was purified via SPE (2 g STMAd MeOH and then NH3 in MeOH,
followed by 2 g SiO2 0−10% MeOH in EtOAc and then 10% MeOH
in DCM) to provide 23 (13 mg, 37%) as a pale yellow solid. 1H NMR
(CD3OD, 400 MHz) δ 1.29 (s, 9H), 3.04 (dd, J = 15.9, 4.1 Hz, 2H),
3.48 (dd, J = 15.9, 9.2 Hz, 2H), 3.63 (br d, 1H), 3.70 (br d, 1H), 3.78
(s, 2H), 3.90 (s, 2H), 4.97 (br s, 2H), 6.84 (dd, J = 7.4, 5.4 Hz, 1H),
6.98 (s, 2H), 7.09 (d, 1H), 7.20 (dd, J = 7.4, 1.5 Hz, 1H), 7.17−7.37
(m, 5H), 7.52 (s, 1H), 8.03 (d, J = 5.3, 1.5 Hz, 1H). UPLC-MS tR
0.64 (592 [M + H]+), 92% pure.
N-(2-((Cyclopropylamino)methyl)benzyl)-N-(2-oxo-2-((2′-oxo-
1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-b]pyridin]-5-yl)-
amino)ethyl)pivalamide (26). 26A (30 mg, 0.059 mmol) was
dissolved in dichloromethane (3 mL), and 26B (8.3 μL, 0.12
mmol) was added. N,N-Diisopropylethylamine (0.028 mL, 0.15
mmol) and magnesium sulfate were added, and the mixture was
stirred at rt. After 6 h, sodium triacetoxyborohydride (20 mg, 0.094
mmol) was added and the reaction was stirred at rt for 48 h. The
reaction was poured into saturated sodium bicarbonate and extracted
three times with dichloromethane. The combined organics were dried
over sodium sulfate, filtered, and evaporated. The crude was purified
via SPE (2 g SiO2 0−12% MeOH in EtOAc) and trituration in diethyl
ether to provide 26 (9 mg, 28%) as a colorless solid. 1H NMR
(CDCl3, 300 MHz) δ 0.27−0.33 (m, 2H), 0.40−0.46 (m, 2H), 1.30
(s, 9H), 2.14−2.22 (m, 1H), 3.05 (dd, J = 15.9, 7.1 Hz, 2H), 3.61
(dd, J = 16.0, 6.8 Hz, 2H), 3.85 (s, 2H), 4.08 (br s, 2H), 5.05 (br s,
2H), 6.82 (dd, J = 7.3, 5.3 Hz, 1H), 7.05−7.13 (m, 2H), 7.27−7.33
(m, 5H), 7.55 (s, 1H), 8.11 (d, J = 5.3, 1.6 Hz, 1H), 8.20 (br s, 1H),
8.58 (br s, 1H). UPLC-MS tR 0.78 (552 [M + H]+), 95% pure.
N-(2-(Azetidin-1-ylmethyl)benzyl)-N-(2-oxo-2-((2′-oxo-1,1′,2′,3-
tetrahydrospiro[indene-2,3′-pyrrolo[2,3-b]pyridine]-5-yl)amino)-
ethyl)pivalamide (27). 27A (30 mg, 0.059 mmol) was dissolved in
dichloromethane (3 mL), and 27B (11 mg, 0.12 mmol) was added.
N,N-Diisopropylethylamine (0.028 mL, 0.15 mmol) and magnesium
sulfate were added, and the mixture was stirred at rt. After 6 h, sodium
triacetoxyborohydride (20 mg, 0.094 mmol) was added and the
reaction was stirred at rt for 30 h. The reaction was poured into
saturated sodium bicarbonate and extracted three times with
dichloromethane. The combined organics were dried over sodium
sulfate, filtered, and evaporated. The crude was purified via SPE (2 g
SiO2 0−10% MeOH in EtOAc and then 10% MeOH in DCM) to
provide 27 (21 mg, 65%) as a colorless glass. 1H NMR (CDCl3, 300
MHz) δ 1.33 (s, 9H), 1.97−2.10 (m, 2H), 3.02 (dd, J = 15.8, 3.5 Hz,
Scheme 6. Synthesis of 7, 8, 23, 26, and 27
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2H), 3.08−3.20 (m, 4H), 3.52−3.66 (m, 4H), 4.07−4.17 (m, 2H),
5.11 (br s, 2H), 6.81 (dd, J = 7.3, 5.3 Hz, 1H), 7.02−7.30 (m, 7H),
7.53 (br s, 1H), 8.13 (d, J = 5.3, 1.4 Hz, 1H), 8.68 (br d, 2H). UPLC-
MS tR 0.78 (552 [M + H]+), 95% pure.
tert-Butyl (2-Oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-
2,3′-pyrrolo[2,3-b]pyridine]-5-yl)amino)ethyl)carbamate (7E/8E).
N,N-Diisopropylethylamine (6.24 mL, 35.8 mmol) was added to a
solution of Boc-glycine-OH (2.4 g, 13.7 mmol), EDCI.HCl (2.52 g,
13.2 mmol), and HOAt (1.8 g, 13.2 mmol) in DMF (25 mL) under
an argon atmosphere. Amine D (3.0 g, 11.9 mmol) was added,
washing in with DMF (10 mL). The mixture was stirred at rt for 18 h,
after which time the reaction was complete as assessed by UPLC-MS.
The mixture was poured into saturated sodium bicarbonate. The
aqueous layer was extracted three times with ethyl acetate. The
combined organic extracts were washed three times with water, 20%
aqueous citric acid, three more times with water, dried over
magnesium sulfate, filtered, and the filtrate was evaporated to provide
the intermediate of 7E/8E (4.84 mg, 99%) as a pale yellow glass. 1H
NMR (CD3OD, 300 MHz) δ 1.45 (s, 9H), 3.06 (dd, J = 15.7, 6.1 Hz,
2H), 3.50 (dd, J = 16.0, 8.2 Hz, 2H), 3.84 (br s, 2H), 6.87 (dd, J =
7.3, 5.3 Hz, 1H), 7.13 (d, J = 7.9 Hz, 1H), 7.22 (d, J = 7.5 Hz, 1H),
7.38 (d, J = 7.8 Hz, 1H), 7.55 (s, 1H), 8.03 (d, J = 3.8 Hz, 1H).
UPLC-MS (CSH 2−50%) tR 0.93 (409 [M + H]+).
2-Amino-N-(2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-
pyrrolo[2,3-b]pyridine]-5-yl)acetamide Dihydrochloride (7E/8E).
An intermediate of 7E/8E (4.84 mL, 11.9 mmol) was triturated in
3 M HCl in cyclopentyl methyl ether (20 mL, 60 mmol) until a
flowing suspension was obtained. The mixture was stirred at rt for 3 h
after which the reaction was judged complete by UPLC-MS. The solid
was isolated by decanting the solvent and then washed and decanted
three times with diethyl ether. The solid was dried to provide 7E/8E
(4.62 mg, quantitative yield) as a beige powder. UPLC-MS (short
basic) tR 0.43 (309 [M + H]+), 93% pure.
N-(2-Oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-
pyrrolo[2,3-b]pyridin]-5-yl)amino)ethyl)-N-((1-phenyl-1H-pyrazol-
5-yl)methyl)pivalamide (7). 7E (52 mg, 0.14 mmol) was dissolved in
dichloromethane (1.4 mL) and tetrahydrofuran (1.4 mL) and then
N,N-diisopropylethylamine (0.065 mL, 0.37 mmol). 1-Phenyl-1H-
pyrazole-5-carbaldehyde (27 mg, 0.16 mmol), sodium triacetoxybor-
ohydride (100 mg, 0.47 mmol), and magnesium sulfate were added,
and the mixture was stirred at rt overnight. The reaction mixture was
filtered, poured into water, and the pH was adjusted to 4 with 2 M
HCl and washed twice with dichloromethane. The aqueous layer was
basified with sodium carbonate and extracted twice with dichloro-
methane. This organic extract was dried over magnesium sulfate,
filtered, and evaporated to provide the intermediate of 7. This
compound was dissolved in dichloromethane (2 mL) under an argon
atmosphere, and N,N-diisopropylethylamine (70 μL, 0.41 mmol) was
added and the mixture was stirred at 5 °C (ice/water).
Trimethylacetyl chloride (258 μL, 0.21 mmol) was added dropwise,
and the mixture was stirred at rt overnight. The reaction mixture was
diluted in dichloromethane, washed with brine and saturated sodium
bicarbonate, dried over magnesium sulfate, filtered, and the filtrate
was evaporated. The residue was purified via MDAP (XBridge C18 19
× 150, 30−60% acetonitrile water with 0.1% ammonium hydroxide)
to provide 7 (11 mg, 14%). 1H NMR (CD3OD, 300 MHz) δ 1.21 (s,
9H), 3.05 (dd, J = 15.9, 2.0 Hz, 2H), 3.48 (dd, J = 15.8, 5.8 Hz, 2H),
4.15 (s, 2H), 4.82 (s, 2H), 6.40 (s, br, 1H), 6.87 (dd, J = 7.1, 5.1 Hz,
1H), 7.12 (dd, J = 7.3, 1.5 Hz, 1H), 7.20 (d, J = 8.1 Hz, 1H), 7.29
(dd, J = 8.1, 1.7 Hz, 1H), 7.41−7.54 (m, 6H), 7.66 (s, 1H), 8.03 (dd,




pivalamide (8). 8E (52 mg, 0.14 mmol) was dissolved in
dichloromethane (1.4 mL) and tetrahydrofuran (1.4 mL) and N,N-
diisopropylethylamine (0.065 mL, 0.37 mmol). Thiazole-2-carbalde-
hyde (15 mg, 0.14 mmol), sodium triacetoxyborohydride (100 mg,
0.47 mmol), and magnesium sulfate were added, and the mixture was
stirred at rt overnight. The reaction mixture was filtered, poured into
water, and the pH was adjusted to 4 with 2 M HCl before being
washed twice with dichloromethane. The aqueous layer was basified
with sodium carbonate and extracted twice with dichloromethane.
This organic extract was dried over magnesium sulfate, filtered, and
evaporated to provide an intermediate of 8. This compound was
dissolved in dichloromethane (2.5 mL) under an argon atmosphere,
and N,N-diisopropylethylamine (70 μL, 0.41 mmol) was added and
the mixture was stirred at 5 °C (ice/water). Trimethylacetyl chloride
(221 μL, 0.18 mmol) was added dropwise, and the mixture was stirred
at rt overnight. The reaction mixture was diluted in dichloromethane,
washed with brine and saturated sodium bicarbonate, dried over
magnesium sulfate, filtered, and the filtrate was evaporated. The
residue was purified via MDAP (XBridge C18 19 × 150, 30−60%
acetonitrile water with 0.1% ammonium hydroxide) to provide 8 (14
mg, 20%). 1H NMR (CD3OD, 300 MHz) δ 1.29 (s, 9H), 3.10 (dd, J
= 15.8, 6.5 Hz, 2H), 3.51 (dd, J = 15.9, 8.2 Hz, 2H), 4.31 (s, 2H),
5.06 (s, 2H), 6.87 (dd, J = 7.4, 5.5 Hz, 1H), 7.12 (dd, J = 7.4, 1.9 Hz,
1H), 7.20−7.25 (m, 1H), 7.35−7.40 (m, 1H), 7.55−7.59 (m, 2H),
7.72−7.75 (m, 1H), 8.03 (dd, J = 5.5, 1.9 Hz, 1H). UPLC-MS (short
basic) tR 1.80 (490 [M + H]+).
Synthesis of 30 (See Scheme 2). (R)-1′-(tert-Butyl)-5-
(dibenzylamino)-1,3-dihydrospiro[indene-2,3′-pyrrolo[2,3-b]-
pyridin]-2′(1′H)-one (33). To a solution of sodium hydroxide (72 g)
in water (60 mL) at room temperature were added toluene (130 mL)
and [2-(chloromethyl)-4-(dibenzylamino)phenyl]methanol hydro-
chloride (4.7 g, 12.1 mmol). The reaction mixture was stirred at
room temperature, while bubbling with argon, for 5 min. Methyl 1-
tert-butyl-2-hydroxy-1H-pyrrolo[2,3-b]pyridine-3-carboxylate (3.0 g,
12.1 mmol) was added in three portions over 10 min. Argon
continued to be bubbled through the stirring solution for 15 min, and
(9R)-1-[3,5-bis(trifluoromethyl)benzyl]cinchonan-1-ium-9-ol bro-
mide (0.7 g, 1.2 mmol) was added in one portion at room
temperature. This mixture was stirred at room temperature for 3 h
under bubbling argon. Water (∼300 mL) was added [note:
exothermic reaction], and the mixture was stirred for ∼15 min
while warming to room temperature. The two layers were separated,
and the aqueous layer was extracted by ethyl acetate. The combined
extracts were washed with water, dried over magnesium sulfate,
filtered, and evaporated to give the crude product of ∼90% purity,
83% ee. This product was dissolved in toluene (60 mL) at 60 °C.
Once totally dissolved, the mixture was warmed to room temperature
and methanol (180 mL) was added. The mixture was stirred at room
temperature for 16 h, and the resulting crystals were collected by
filtration and washed with methanol to give 33 (61%, 96% ee). The
product was further recrystallized using toluene (50 mL) and
methanol (120 mL) to give 3.1 g (52%, >99% ee) of the product.
1H NMR (CD3OD, 400 MHz) δ 1.82 (s, 9H), 2.88 (dd, J = 15.2, 11.8
Hz, 2H), 3.48 (t, J = 15.3 Hz, 2H), 4.67 (s, br, 4H), 6.67 (s, br, 1H),
6.78 (dd, J = 7.1, 5.3 Hz, 1H), 7.01−7.14 (m, 2H), 7.25−7.40 (m,
11H), 8.15 (dd, J = 5.2, 1.7 Hz, 1H); LC-MS (488.27 [M + H]+).
Chiral HPLC: Phenomenex Lux 3μ Cellulose-1 column; nhexane/
isopropanol, 95:5; flow rate = 1.0 mL/min; detection at 254 nm.
(R)-5-Amino-1,3-dihydrospiro[indene-2,3′-pyrrolo[2,3-b]-
pyridin]-2′(1′H)-one (30). To a solution of 33 (3.1 g, 6.36 mmol) in
methanol (120 mL) was added methanesulfonic acid (11 mL) at
room temperature. The mixture was stirred at reflux for 4 h. The
methanol was removed under vacuum, and water (∼100 mL) was
added to the mixture, and pH was adjusted to ∼ 10 by adding a 50%
aqueous solution of sodium hydroxide. The aqueous layer was
extracted with ethyl acetate, and the combined extracts were dried
over magnesium sulfate, filtered, and evaporated to give the crude
product. The crude product was dissolved in methanol (∼80 mL),
and Pd/C (0.1 g) was added to the solution followed by concentrated
HCl (7 mL). The mixture was stirred at room temperature under a
balloon of H2 overnight. Volatiles were removed to dryness, and the
crude material was then dissolved in dichloromethane. Water followed
by saturated aqueous potassium carbonate was added to pH ∼ 10.
The mixture was extracted by dichloromethane, dried over
magnesium sulfate, filtered, and evaporated to give 1.2 g (77%,
>99% ee) of the desired product 30. This compound was used directly
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in the next step without further purification. 1H NMR (CD3OD, 400
MHz) δ 2.94 (dd, J = 15.3, 4.4 Hz, 2H), 3.46 (t, J = 14.0 Hz, 2H),
6.65 (d, J = 8.1 Hz, 1H), 6.69 (s, br, 1H), 6.88 (dd, J = 8.9, 3.8 Hz,
1H), 7.02 (d, J = 8.1 Hz, 1H), 7.13 (d, J = 7.3 Hz, 1H), 8.02−8.06
(m, 1H); LC-MS (252.11 [M + H]+); [α]D
22 = +63.6 (c 1.1, MeOH).
Chiral HPLC: Phenomenex Lux 3μ Cellulose-1 column; nhexane/
isopropanol, 40:60; flow rate = 0.5 mL/min; detection at 220 nm.
Synthesis of (R)-25. This compound was synthesized according
to the experimental procedure described for 25 using 30 instead of D
(see Scheme 4).34 Analytical data for (R)-25: 1H NMR (CD3OD, 300
MHz) δ 1.32 (s, 9H), 2.41 (s, 3H), 3.04 (dd, J = 15.9, 3.9 Hz, 2H),
3.50 (dd, J = 15.8, 7.4 Hz, 2H), 3.72 (s, 2H), 4.11 (br s, 2H), 4.96 (br
s, 2H), 6.86 (dd, J = 7.4, 5.4 Hz, 1H), 7.08−7.14 (m, 1H), 7.17−7.23
(m, 2H), 7.26−7.37 (m, 4H), 7.52 (s, 1H), 8.03 (d, J = 5.4, 1.6 Hz,
1H); [α]D
22 = +40.8 (c 1.0, MeOH).
Cell Lines and Culture Conditions. All cell lines were purchased
from ATCC, Cell Applications, Inc., or DiscoverX with proof of
authentication, unless stated. All cell lines were maintained at 37 °C in
a humidified atmosphere with 5% CO2. Human breast cancer cells
MDA-MB-231 (ATCC, HTB-26) were cultured in RPMI 1640
medium, GlutaMAX supplement (Thermo Fisher Scientific, 61870-
036) containing 10% (v/v) fetal bovine serum (FBS, Thermo Fisher
Scientific, 10500-064), and 1% (v/v) penicillin−streptomycin (Sigma-
Aldrich, P4333). CGRP (95-0164C6) receptor- and AM2 (95-
0169C6) receptor-overexpressing cell lines were obtained from
DiscoverX and cultured in AssayComplete Cell Culture Kit 105
(92-3105G) supplemented with 800 μg/mL G418 and 2.5 μg/mL
puromycin. The receptor component expression of these cells was
validated in-house previously.34
Time-Resolved Fluorescence Resonance Energy-Transfer
(TR-FRET) cAMP Accumulation. The ability of the compounds to
inhibit cAMP production induced by an EC50 concentration of the
maximum agonist activation (information previously published34) in
GPCR/RAMP-overexpressing cells (i.e., AM2, CGRP cells) was
evaluated using cAMP accumulation assays. Each compound was
tested at 8 full-log concentrations (10−11−10−5 M) including a
negative control (blank). The total cAMP was measured using the
TR-FRET LANCE cAMP detection kit (PerkinElmer, AD0264), as
described previously.34 Briefly, frozen cells (2 × 106 in each well)
were thawed and prepared in warm stimulation buffer (1× HBSS, 5
mM N-(2-hydroxyethyl)piperazine-N′-ethanesulfonic acid (HEPES),
0.5 mM IBMX, and 0.1% bovine serum albumin (BSA)). Alexa Fluor
conjugated anti-cAMP (1:100 concentration) was then added to the
cell suspension, and cells were plated (2500 cells, 6 μL) in a 384-well
white opaque microtiter plate (OptiPlates, PerkinElmer, 6007299).
Cells were first preincubated with serial dilutions (3 μL) of the
antagonists for 30 min at room temperature prior to their stimulation
with the EC50 value of agonist (3 μL) for 15 min at room
temperature. Subsequently, a 12 μL detection mix (Europium-Chelate
streptavidin/biotinylated cAMP) was added to stop the reaction and
induce cell lysis. TR-FRET was detected after an hour of incubation
by an EnSight multimode Plate reader (PerkinElmer) at 320/340 nm
excitation and 615/665 nm emission. Data were normalized to agonist
only and blank (stimulation buffer only) wells as 0 and 100% cAMP
inhibition, respectively.
The final DMSO concentration was below 0.5%, and this was kept
consistent in all of the wells, including agonist alone and blank. The
same methodology including the number of cells was used for all cell
lines. Concentration−response curves were analyzed using three-
parameter logistic curve fitting to determine IC50 values (Graphpad
Prism 7 and 8). No further constraints in any parameters of the curves
were used.
Real-Time-Glo MT Viability Assay. Cell viability in human
breast cancer cells (MDA-MB-231) was quantified using Real-Time-
Glo MT Cell Viability Assay (Promega, G9712) as previously
described.34 Cells (2000 cells) were seeded into 96-well white clear-
bottom plates (Corning, 3903) in full serum media overnight before
washing and changing to suboptimal media (RPMI + 5% FBS + 1%
P/S) containing Real-Time-Glo reagents according to the Promega
protocol. A baseline luminescence read (prior to treatment) was taken
using an EnSight Multimode Plate Reader (PerkinElmer) after an
hour of incubation at 37 °C. Cells were then treated with compounds
or vehicle control (PBS + 0.05% DMSO) daily. Results were
normalized to vehicle-treated controls as 100% viable (Graphpad
Prism 7 and 8).
Ethical Statement for In Vivo Studies. The in vivo study plans
were assessed by a local research ethics committee before submission
for Home Office approval. All in vivo experiments were carried out
under the authority of project and personal licenses granted by the
U.K. Home Office under the U.K. Animals (Scientific Procedures)
Act 1986 (ASPA).
In Vivo Efficacy Model. The study was performed using 6−7
week old BALB/c nude female mice, with a weight range of 15−20 g.
Animals were provided by Envigo Corporation (Cambridgeshire,
U.K.) or Charles River Laboratories (Massachusetts) depending on
availability. Each experiment started with 10 mice (experimental
units) in each experimental/control group. Subsequent analysis
(tumor growth and histology) was only performed in animals where
tumors had established and were palpable within 3 days of
implantation. This was in accordance with the power calculation
performed to ensure robust statistical analysis by the University of
Sheffield Statistical Service. The animals were housed in individually
ventilated cages (with the appropriate bedding and flooring
conditions) in environmentally controlled conditions with a 12 h
light/dark cycles at ∼26 °C. Mice had access to an adequate amount
of water and a 2018 Teklad Global 18% Protein Rodent Diet
containing 1.01% calcium (Harlan Laboratories, U.K.). The day-to-
day care of the animals was carried out by the technicians in the
Biological Services (The University of Sheffield, U.K.). All scientific
procedures on animals were carried under the U.K. Home Office
Project Licenses (40/3499) and Procedure Individual Licenses.
Compound Preparation for In Vivo Studies. Compounds were
dissolved in DMSO (Sigma-Aldrich, D4540) and sonicated at 37 °C
for 10 min. The appropriate volume of solvent (Kolliphor HS15 (1
part, grams), Kollisolv PEG E 400 (3 parts, mL), and PBS (6 parts,
mL)) was then added to yield a 6% DMSO/94% solvent solution.
These working stocks (8 mg/mL) were further sonicated at 37 °C for
10 min before storing at −20 °C. To make treatment aliquots, equal
amounts of the working stock (or vehicle control) and solvent were
mixed and sonicated at 37 °C for 10 min (4 mg/mL, equivalent to 20
mg/kg, 3% DMSO/97% solvent). Vehicle control and compounds
were sonicated at 37 °C for 10 min prior to ip injections (200 μL per
mouse).
Cell Preparation and Tumor Inoculation. Cells were prepared
according to standard cell culture techniques. Cell pellets were
resuspended in 50% PBS/50% Matrigel (Corning, 354234). Matrigel/
PBS cell suspension, needles (25G), and syringes (1 mL) were kept
on ice before and during tumor inoculation into mice. Cell suspension
(100 μL, 5 × 106 cells) was injected subcutaneously into the left flank
of 6−7 weeks old female immunodeficient nude athymic mice
(BALB/c nude). Once the tumors became palpable (around 100
mm3), mice were randomized into treatment groups. Mice were
treated daily at the same time of the day with an ip injection of 20
mg/kg of compound or vehicle control (200 μL per mouse) until
humane end point. Mice were observed for at least 30 min post
treatment to detect any acute adverse effects. Tumor size and mouse
weights were measured twice a week. At the end of each study, the
animals were euthanized following the appropriate procedures listed
in the ASPA Act 1986. Vital organs and tumors were stored in 10%
neutral-buffered formalin for further histological analysis. The primary
experimental outcome was tumor volume. The percentage tumor
volume was calculated by normalizing measured tumor volumes to the
initial tumor volume prior to the start of treatment on day 5. Simple
linear regression was done to compare the line of best fit between the
growth curves. Blinding was not used for the in vivo studies.
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